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Abstract 
Elevated levels of the inflammatory cytokine interleukin-6, IL-6, have been linked 
with poor prognosis in ovarian cancer patients by influencing tumour growth, 
invasion, angiogenesis and chemo-resistance. A clinical trial conducted in parallel with 
pre-clinical studies showed an anti-IL-6 antibody to have some activity in ovarian 
cancer patients and in xenograft models, via reduction in pro-inflammatory and 
angiogenic factors such as TNF-α, IL-8 and VEGF. Anti-IL-6 treatment also showed 
significant reductions in vascular area with decreased expression of an angiogenic 
factor Jagged1. 
The aim of my study was to investigate the effects of IL-6 on normal and tumour 
angiogenesis. I found that recombinant IL-6 stimulates angiogenesis in mouse and rat 
aortic ring assays and that it can also stimulate growth and migration of endothelial 
cells in vitro. IL-6 has similar potency as VEGF in inducing vessel sprouting. IL-6 
itself does not induce VEGF in the endothelial cells I tested. Investigation of the 
effects of IL-6 on vessel maturation revealed a significant reduction in pericyte 
coverage of vessels treated with IL-6 compared with VEGF. Collectively, these data 
led to my hypothesis that ‘IL-6 drives aberrant angiogenesis, independent of VEGF 
signalling’. 
Investigating the mechanism by which IL-6 drives angiogenesis and leads to defective 
pericyte formation, I showed a link between IL-6 and the Notch ligands, Jagged1 and 
DLL4. My data suggested that IL-6 could stimulate Jagged1 in endothelial cells, 
whereas VEGF induces DLL4, the Notch ligand known to be involved in inducing 
stalk phenotype. Exploring previous findings to get a better understanding of the 
interaction of Notch ligands and pericyte recruitment also suggested a role of 
Angiopoeitin-2 in relation to IL-6 signalling. These observations were extended in 
IGROV-1 ovarian cancer xenografts treated with an anti-IL-6 antibody and by 
analysis of gene expression datasets from ovarian cancer biopsies. My results suggest 
therapeutic potential of combining inhibitors of IL-6 and VEGF in ovarian cancer.  
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1 Introduction 
 
The aim of this thesis is to study the effects of IL-6 on normal and tumour 
angiogenesis with a focus on ovarian cancer.  
1.1 Ovarian cancer 
 
Ovarian cancer is the most lethal gynaecological malignancy and is the 4th most 
common cause of cancer-related death in women [1]. It is now clear that the term 
‘ovarian cancer’ refers to a number of distinct diseases, with different genetic drivers 
that share a common anatomical location in the peritoneum [2]. ‘Ovarian cancer’ is 
normally categorised depending on its malignant potential. Low-grade malignancies 
are often characterised by RAS/RAF mutations and their tissue of origin is not 
entirely clear but may be the ovary [3]. Among the high-grade malignancies, there 
are two subtypes which probably arise from endometriosis via retrograde 
menstruation: endometrioid ovarian cancer and clear cell carcinoma (CCC). CCC is 
characterised by a common genetic mutation in ARID1A (AT – rich interactive 
domain-containing protein 1A) [4]. It is also characterised by a strong HIF-STAT3-
IL-6 signature [5]. Another high-grade tumour is mucinous ovarian cancer, which is 
most likely metastases from intestinal or stomach malignancies. Finally, high-grade 
serous ovarian cancers (HGSC) are aggressive and have high invasive potential 
(Figure 1.1).  These tumours may arise from the fallopian tube or mullerian 
epithelium rather than the ovary. They are known to disseminate early and spread 
extensively throughout the peritoneal space resulting in multiple lesions, which are 
difficult to treat [6, 7]. 96% of HGSC tumours have TP53 mutations and about 50% 
will also have abnormalities related to the homologous recombinant repair (HRR) 
pathway. Apart from this, HGSC exhibit a great deal of molecular heterogeneity. The 
cancer genome atlas project also identified seven other significantly mutated genes in 
2-6% of HGSC samples, including mutations in CCNE1, RB, PI3K/RAS and the 
NOTCH pathway [8].  
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Figure 1.1 The pathogenesis of ovarian cancer.  
Most of the invasive cancers that are termed ‘ovarian’ are derived from different tissues. Cancers that 
arise from the colon, stomach or appendix often metastasise and lead to invasive mucinous ovarian 
cancer. Endometriosis caused by retrograde menstruation has been shown to be the source of clear cell 
and endometrioid cancers. HGSC can arise from the surface of the ovaries or the fimbria of the 
fallopian tubes [2]. 
 
For the past 50 years treatment strategies for ovarian cancer have included radical 
surgery and platinum based chemotherapy with advances in the chemotherapy only 
leading to small improvements in outcome [9]. Due to the complexity of ovarian 
carcinogenesis there have been many flaws in understanding its nature, which has 
had an impact on the treatment of the disease [10].  
Certain types of ‘ovarian’ cancer have more similarity with renal or breast cancer 
than other subtypes of ovarian cancer. Now that there is a clearer idea on the 
distinction between the different subtypes of ‘ovarian’ cancer and its pathogenesis, 
the focus is on developing and improving targeted therapies for each subtype of the 
disease [11].  
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1.2 Pathogenesis of HGSC 
 
The earliest view of ovarian cancer asserts that all different subtypes of ovarian 
cancer arise from a common origin in the ovarian surface epithelium (OSE) [12]. 
This is a result of the physical trauma inflicted on the ovarian surface due to follicular 
rupture and oocyte release during the process of ovulation [13]. It was believed that 
the constant damage and repair of the OSE could facilitate tissue remodelling and 
lead to metaplastic change from an epithelial to mesenchymal phenotype. Ovulation-
associated inflammatory cytokines and reactive oxygen species could also lead to 
DNA damage of the OSE cells and these DNA damaging processes also increased 
the risk of transformation of the OSE. Another theory associated with the ovarian 
surface origin is the development of numerous invaginations of the epithelial cells into 
the cortical stroma [6]. These invaginations were frequently found trapped within the 
stroma in circular structures called cortical inclusion cysts. There are several growth 
hormones acting upon the ovary that can induce proliferation of the epithelial cells 
within the cortical inclusion cysts. In cases where these epithelial cells undergo DNA 
damage, the theory suggested that they would be major targets for neoplastic 
transformation, which could ultimately give rise to ovarian carcinomas [13].  
However this theory of the OSE and the cortical inclusion cysts was questioned due 
to the differences in the outcomes and genetic phenotype of the different ovarian 
tumours that arise from the cortical inclusion cysts within the ovaries [14]. 
Recent studies suggest that most HGSC malignancies may have a fallopian tube 
origin [15]. One of the earliest findings linking the fallopian tube pathway to HGSC 
malignancies came from the study carried out by Callahan et al in BRCA mutation 
carriers. In that study, primary fallopian tube malignancies were detected in BRCA-
positive women undergoing surgery for ovarian cancer risk reduction [16]. The 
fimbria of the distal fallopian tube was found to be the dominant site of origin for 
early malignancies in BRCA carriers. Immunohistochemistry staining of these serous 
intraepithelial carcinomas (STIC) revealed p53 mutations in 80% of the cases [10]. 
The next major link was proposed from a study carried out by Crum et al, which 
indicated that 70% of sporadic (nonhereditary) HGSCs have tubal involvement 
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including STICs [17]. These studies suggest that at least some HGSC arise from 
fallopian tube/fimbria and subsequently metastasise to the ovaries. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Emergence of HGSC from the fimbrinated end of the fallopian tube 
and spread to the ovarian surface epithelium.  
Majority of HGSC (bottom inset) emerge from secretory cells (top inset) found in the fimbria of the 
fallopian tube and spread to the OSE where the bulk of the tumour resides [1].  
 
There is a possible mechanism that would incorporate both theories; the ovarian 
cortical inclusion cysts and the fimbrial origin of ovarian cancer. According to this 
hypothesis, the fimbria come into close contact with the ovary and shed tubal 
epithelial cells on the disrupted ovarian surface to form a cortical inclusion cyst 
(Figure 1.2) [18]. This theory suggests that some ‘ovarian cancers’ may arise from 
ovarian inclusion cysts, but these cysts come from implanted fallopian tube fimbrial 
deposits. Follicular fluid containing reactive oxygen species can act on the OSE and 
further contribute to ovarian carcinogenesis [13]. 
 
Experiments using mouse models have shown that the fallopian tube can not only 
initiate but can also advance de novo to the full spectrum of the metastatic 
malignancy of HGSC. A recent study by Perets et al, generated a mouse model of 
HGSC using the PAX8 promoter to disrupt commonly altered genes such as 
HGSC 
FTSE
C 
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BRCA1/2, TP53 and PTEN selectively in the fallopian tube secretary epithelial cells 
(FTSEC) [19]. In this mouse model they observed precursor STIC lesions progress 
to advanced stage disease with ovarian and peritoneal metastasis. This study showed 
that HGSC could arise from FTSEC and lead to pre-invasive lesions, which then 
spread to the ovaries. Even though the majority of mice displayed STIC lesions, on 
gross inspection the fallopian tube appeared normal, whereas the ovary often showed 
visible signs of the disease. This observation is generally made in human disease and 
it explains the predisposition to term this disease as ‘Ovarian cancer’ [19].  
1.3 Treatment for HGSC  
 
The 5-year survival rate for HGSC patients is between 35% and 40% and this is 
strongly influenced by the stage of the disease at presentation. The current first line 
treatment for HGSC involves surgical debulking in combination with platinum with 
or without taxane chemotherapy [20]. Several clinical features such as tumour grade, 
size of the tumour after primary cytoreduction and general patient fitness are 
considered before implementing therapies of anticancer agents. The major challenge 
of the treatment is disease relapse of chemoresistant cells [21].  
Women with germline mutations in HRR genes respond better to chemotherapy with 
longer progression free and overall survival compared with non-carriers [22, 23]. 
This is because the defect in HRR associated with loss of BRCA function increases 
the sensitivity of the ovarian cancer to platinum with or without taxane 
chemotherapy. These patients also benefit from treatment with PARP inhibitors [24].  
Studies are also being carried out to understand the role of host cells in the growth 
and metastasis of the tumour cells. The tumour microenvironment has become an 
attractive target for the development of therapies, which will improve the standard 
treatment. This field of research is supported by the ongoing success witnessed in the 
clinical trials carried out with the anti-angiogenic agents to target the tumour 
vasculature [25]. A Phase III clinical trial with the angiogenic inhibitor bevacizumab, 
during and after treatment with chemotherapy, resulted in a significant increase in 
progression free survival in HGSC patients [21].  
Another area which is of interest is the inflammatory cytokine and chemokine 
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networks in ovarian cancer [26]. Studies have identified a cytokine network within 
the ovarian cancer microenvironment, which has a profound effect on tumour 
growth, angiogenesis and leucocyte infiltrate. One of the earliest studied 
inflammatory cytokines in ovarian cancer is tumour necrosis factor-alpha (TNF-α) 
[27]. TNF-α is also involved in HGSC progression by acting as a principle mediator 
between other cytokines/chemokines. My lab has previously shown that the 
cytokines TNF-α, interleukin-6 (IL-6), the chemokine CXCL12 and its receptor 
CXCR4, were constitutively expressed and co-regulated in ovarian cancer cells in 
vitro. This was followed by the identification of the co-expression and co-regulation of 
this cytokine network in human ovarian cancer biopsies, which is now described as 
the ‘TNF-network’. With the use of gene expression arrays they went on to show the 
involvement of TNF in angiogenesis, inflammation and NOTCH signalling in 
ovarian cancer tumour microenvironment [28, 29]. 
 
TNF-α was also involved in development of metastases and neo-vascularisation of 
tumours in HGSC xenograft models. The study also showed that the tumour growth 
and metastasis were significantly reduced with a stable knockdown of TNF-α in 
malignant cells [30]. This led to the use of anti-TNF-α antibodies in phase I trial for 
the treatment of recurrent ovarian cancer. The results from the trial showed disease 
stabilisation in six of the 18 patients who received treatment for minimum of twelve 
weeks. There was also a drop in levels of IL-6 and CCL2 in more than half of the 
patients. All these studies collectively showed the importance of 
inflammation/inflammatory cytokine and HGSC in the context of tumour 
progression.  
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1.4 Inflammation and Cancer 
 
In the last decade inflammation has been shown to foster multiple hallmarks of 
cancer by providing ‘bioactive molecules to the tumour microenvironment, including 
growth factors that sustain proliferative signalling, survival factors that limit cell 
death, pro-angiogenic factors and extracellular matrix-modifying enzymes that 
facilitate angiogenesis, invasion and metastasis’ [31]. Epidemiological studies also 
revealed that 15-20% of cancer-related deaths are linked to infections and 
inflammatory responses. There are two pathways connecting cancer and 
inflammation; the intrinsic and extrinsic pathway [32]. The intrinsic pathway is 
activated by genetic events such as activation of oncogenes or by inactivation of 
tumour suppressor genes resulting in transformation of cells into a malignant 
phenotype. Cytokines and chemokines are produced by these malignant cells 
downstream of the oncogenic events. Hence, these transformed cells can trigger the 
production of inflammatory mediators, which can lead to the development of an 
inflammatory microenvironment in a tumour that did not have a predisposed 
inflammatory condition [33].  
In the extrinsic pathway, infections or inflammatory conditions such as pancreatitis 
or colitis can predispose to cancers such as pancreatic or colorectal cancer. Both the 
intrinsic and extrinsic pathways lead to activation of transcription factors such as 
nuclear factor kappa beta (NFκB), signal transducer and activator of transcription 3 
(STAT3) and hypoxia-inducible factor-1α (HIF-1α) in tumour cells which then lead 
to production of inflammatory mediators such as cytokines and chemokines (Figure 
1.3). These cytokines can lead to activation of the same key transcription factors in 
inflammatory cells and stromal cells resulting in further induction of inflammatory 
mediators leading to a cancer-related inflammatory microenvironment. This 
microenvironment can then enhance tumour proliferation, cell survival, migration 
and invasion [34].  
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Figure 1.3 The intrinsic and extrinsic pathway that connect cancer and 
inflammation.  
The intrinsic pathway is activated by genetic events that cause malignant transformation and the 
extrinsic pathway is activated by inflammatory or infectious conditions. Both of the pathways lead to 
the activation of transcription factors involved in growth, survival and invasion of cancer cells [34].  
Pro-inflammatory cytokines and chemokines mediate interactions between the 
malignant and stromal cells in the ovarian cancer microenvironment. IL-6 is one of 
the most important cytokine in HGSC [35]. This cytokine is involved in HGSC 
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progression and invasion as demonstrated in various animal models and in human 
ovarian biopsy tissue [28, 29]. 
1.5 IL-6 
 
IL-6 is a cytokine involved in various biological functions including the immune 
response and haematopoiesis. A number of cell types, including T cells, macrophages 
and endothelial cells, produce IL-6 (Figure 1.4) [36]. Activation of the IL-6 gene is 
mediated through the interaction of a number of transcription factors, including NF-
κB, AP-1, CCAAT enhancer binding protein β (CEBPβ; formerly known as nuclear 
factor IL-6 (NF-IL6)) and the multiple response element (MRE) [37]. 
 
Figure 1.4 IL-6 producing cells and its target cells.  
IL-6 is produced by lymphoid and non-lymphoid cells, such as T cells, B cells, monocytes, fibroblasts, 
keratinocytes, endothelial cells and mesangial cells. IL-6 has a wide range of biological activities on 
various target cells [38]. 
 
1.6 IL-6 signalling 
 
IL-6 acts through the formation of a high affinity complex with its receptor, which 
has two components: the ligand binding 80kDa IL-6 receptor alpha (IL-6Rα) and its 
signal transducing glycoprotein 130 (gp130) [39]. IL-6Rα is predominantly restricted 
to cell types such as hepatocytes, leukocytes and some tumour cells, whereas the 
    IL-6 producing cells 
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signal transducing gp130 unit is ubiquitously expressed. Cells also express a soluble 
form of IL-6Rα (sIL-6Rα) which is produced by proteolysis of the membrane bound 
IL-6Rα [40]. 
   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Schematic representations of two types of IL-6 signalling, Classic and Trans-
signalling.   
Classic signalling (A) in which IL-6 binds to IL-6Rα, which forms a complex with gp130 to initiate 
downstream signalling. Trans- signalling (B) in which IL-6 signalling is mediated through binding of 
IL-6 to sIL-6Rα and subsequent interaction of this complex with the membrane associated gp130. 
 
As represented in Figure 1.5A, in the classic signalling pathway, IL-6 ligands bind 
with high affinity to cells that express membrane bound IL-6Rα. The IL-6/IL-6Rα 
then recruits the signal transducing gp130 unit, thereby activating IL-6 downstream 
signalling [41]. In trans-signalling (Figure 1.5B), IL-6 binds to the sIL-6Rα, which 
then associates with any cell that expresses the gp130 unit, thereby activating IL-6 
signalling in cells, which do not express the membrane-bound IL-6Rα. Numerous 
studies have shown that a soluble version of the gp130 unit is capable of inhibiting 
the trans-signalling by binding to the IL-6/sIL-6Rα complex and blocking it from 
binding to the membrane bound form of gp130 [39]. 
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1.7 Activation of the IL-6 receptor 
 
The formation of a complex between the (IL-6)/(IL-6R) and signal transducing unit 
gp130 complex results in downstream activation of JAK1, JAK2, Tyk2 and in the 
phosphorylation of a specific tyrosine residue on the receptor. STAT3 then binds to 
this receptor and is phosphorylated by JAK [42]. Phosphorylated STAT3 (pSTAT3) 
dimerises and is recruited to the nucleus where it acts as a transcription factor 
(Figure 1.6). STAT3 regulates the transcription of genes such as Bcl2, Bcl-xl, cJun 
and cFos, which play a key role in cell growth and differentiation and in the 
inhibition of apoptosis. RAS is also activated in response to IL-6, and leads to hyper-
phosphorylation and activation of mitogen activated phosphate kinase (MAPK) [43]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 IL-6 and its downstream signalling targets.  
Formation of the IL-6/IL-6Rα and gp130 complex leads to the activation of its direct downstream 
target STAT3. It can also activate the MAPK and PI3K pathway.  
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1.8 IL-6 and cancer  
 
Various chronic conditions such as inflammatory bowel disease, rheumatoid arthritis 
and several malignancies, such as colon cancer, have been linked to inappropriate IL-
6 trans-signalling [39, 44]. More than 50% of all cancers have aberrant STAT3 
signalling which renders malignant cells resistant to apoptosis and increases their rate 
of proliferation, thereby enhancing tumourigenesis [45]. STAT3 regulates genes that 
are involved in proliferation, such as cyclin D1, c-myc and genes that suppress 
apoptosis, such as the Bcl-2 family members Mcl-1 and Bcl-xl. It can also promote 
angiogenesis and metastasis by up-regulating pro-angiogenic molecules like VEGF 
and matrix metalloproteinase-9 (MMP-9).  
Other studies have also shown a role for IL-6 in increasing resistance to 
chemotherapy via the JAK/STAT signalling pathway [46, 47]. The tumour 
promoting actions of IL-6 are mediated by its role in cytokine networks found in 
several human malignancies such as serous and clear cell ovarian cancer [5, 29], 
multiple myeloma [48], Castleman’s disease [49] and hepatocellular carcinoma [36].  
Over the years, there have been several studies linking IL-6 with various cancers. 
Most of the findings from these studies have associated IL-6 with poor prognosis and 
disease progression as shown in Table 1. 
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Table 1 Clinical association data of IL-6 with various cancer types.  
     Data adapted from [50]. 
Cancer type                               Role of IL-6 
Intestine High serum IL-6 correlates with advanced stage and poor 
prognosis 
Stomach High levels of IL-6 in the serum is an independent predictor of 
poor prognosis 
Liver In hepatocellular carcinoma high serum levels of IL-6 correlate 
with poor prognosis 
Pancreas High levels of IL-6 in pancreatic cancer patient serum is linked to 
poor overall survival 
Lung High serum levels of IL-6 correlate with poor survival in non 
small cell lung cancer 
Esophagus Elevated serum levels of IL-6 are correlated with disease 
progression and poor prognosis 
Breast High systemic levels of IL-6 has been shown to correlate with 
poor prognosis and metastasis 
Cervix High serum levels of IL-6 correlates with disease progression  
Ovary High IL-6 level in serum and ascites correlates with poor 
prognosis 
Prostate High serum IL-6 is linked to poor prognosis and chemoresistance 
Kidney High serum IL-6 levels correlate with tumour size, stage and poor 
prognosis 
Bladder High IL-6 expression correlates with poor prognosis 
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Due to this clinical association of IL-6 with disease progression or poor outcome, 
pre-clinical and in vivo studies have been carried out to understand the role of IL-6 
in various cancer models [35, 51, 52]. 
IL-6 promotes proliferation and survival of colon cancer cells via induction of STAT3 
[53]. The sIL-6Rα shedding within the tumour microenvironment can activate 
STAT3 in cells expressing gp130 but lacking the membrane bound IL-6Rα [54].  In 
addition to STAT3, there are other signalling molecules, which are activated by 
gp130 such as the Ras-MAPK and the PI3K-mTOR pathways that also play a role in 
tumour progression [55].  
Mouse models of colitis associated cancer (CAC) have shown hematopoietic cells, 
especially macrophages and dendritic cells to be involved in production of IL-6 
during early stages of tumour induction, followed by T cells during later stages of 
tumour progression. In vivo CAC studies with a neutralising antibody against IL-6Rα 
or a sgp130Fc fusion protein led to inhibition of tumour growth [54]. Deletion of 
STAT3 also resulted in the reduction of number of early adenomas in adenomatous 
polyposis coli (APC) mice [56].  
Hepatocellular carcinoma (HCC) is another inflammation related cancer where IL-6 
is linked with poor prognosis [56]. Kupffer cells and recruited macrophages are 
mainly responsible for IL-6 production in these tumour cells and hepatocytes also 
express high levels of IL-6Rα and gp130. The tumour promoting actions of IL-6 in 
HCC are mediated via STAT3 and targeting STAT3 in hepatocytes inhibits HCC 
development [57]. Studies investigating a liver specific knock out of SOCS3, an 
inhibitor of IL-6, led to enhanced HCC progression as a result of increased STAT3 
and pERK activation [58]. In vitro IL-6 knockdown in HCC cell lines also resulted in 
inhibition of proliferation, migration and invasion confirming the importance of 
autocrine IL-6 signalling in this model of cancer.  
Studies in Kras driven models of pancreatic ductal adenocarcinoma (PDAC) have 
shown the importance of STAT3 activation in the initiation and the progression of 
the disease [59]. In human esophageal cancer cells, IL-6 acts as an anti-apoptotic 
factor via induction of STAT3 and ERK signalling. Blocking IL-6 expression in these 
cell lines led to inhibition of aggressive tumour phenotype and overcame radiation 
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resistance in vitro and in vivo [60].  In breast cancer, IL-6 signalling plays a major role 
controlling cancer cell proliferation, cancer stem cell renewal and metastasis [61]. 
Cancer associated fibroblasts that stimulate angiogenesis and invasion also express 
high levels of IL-6. IL-6 induced Notch-3 dependent up-regulation of Jagged1 can 
also promote growth of breast cancer cells [62]. 
In prostate cancer, IL-6/STAT3 signalling results in transition from hormone 
sensitive to hormone resistant phenotype and it also leads to induction of myeloid 
derived suppressor cells (MDSCs). In vivo studies have indicated the activation of 
STAT3 in the development of castration resistant prostate cancer [63].  
Pre-clinical studies exploring the regulation of IL-6 in ovarian cancer cell lines have 
established a link between high levels of IL-6 and p53 status. Wild-type p53 inhibits 
IL-6 promoter activity. 96% of the HGSC have a p53 mutation, which may increase 
IL-6 promoter activity [8, 37]. There have been studies showing that some of the 
ovarian cancer cell lines constitutively produce IL-6 and this production is enhanced 
when these cells are co-cultured with other cytokines/chemokines from the ovarian 
cancer microenvironment [29]. 
1.9 Clinical trials targeting IL-6 
 
A neutralising anti-IL-6 antibody was initially tested in patients with prostate cancer. 
This was because the pre-clinical studies in prostate cancer showed IL-6 production 
to be associated with conversion of prostate cancer cells from an androgen-dependent 
to an androgen-independent phenotype, resulting in increased proliferation and 
decreased apoptosis [64]. These results led to a clinical trial with siltuximab in 
castrate resistant prostate cancer patients whose disease had progressed after 
docetaxel chemotherapy. The trial showed siltuximab to have biological activity in 
patients with decrease in c-reactive protein levels (CRP) in blood. High levels of 
CRP are linked to poor prognosis in prostate cancer patients. However, there was 
minimal clinical activity with siltuximab as a monotherapy. The paper suggested 
additional studies with siltuximab in combination with chemotherapy [65]. 
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Another study investigated the role of IL-6 in paraneoplastic thrombocytosis; the 
raised platelet count seen in cancer patients, especially in HGSC. The study proposed 
that IL-6 made by the malignant cells stimulates thrombopoietin production in the 
liver, which increases platelet production in the bone marrow. Therefore countering 
paraneoplastic thrombocytosis by directly or indirectly targeting IL-6 was considered 
a potential therapeutic approach. Siltuximab treatment significantly reduced platelet 
count in tumour bearing mice and in patients with ovarian cancer. The study also 
indicated that treatment of tumour bearing mice with anti-platelet antibody resulted 
in decreased tumour growth and significantly diminished tumour vascular areas [66]. 
Currently there are several Phase II studies being carried with siltuximab in cancers 
such as transplant-refractory melanoma, castrate resistant prostate cancer and 
metastatic renal cell carcinoma. There are also other IL-6 targeting antibodies such as 
sirukumab, olokizukmab, elsilimomab, clazakizumab and MEDI5117, which are 
being tested in Phase I/II clinical trials in rheumatoid arthritis, inflammatory bowel 
diseases and in some cancer types [50].  
Another approach undertaken to target the IL-6 signalling is by using antibodies 
such as Tocilizumab, which blocks the IL-6Rα. These antibodies have been 
successful and are approved for the treatment of rheumatoid arthritis and 
Castleman’s disease in Japan [67]. Also another emerging class of drugs, which are 
now used in clinical trials to target the downstream IL-6 signalling, are JAK 
inhibitors.  There are several of these inhibitors in Phase I/II clinical trials in 
rheumatoid arthritis, haematological malignancies and various solid tumours [50]. 
Among all the pre-clinical and clinical studies carried out with IL-6 targeting agents, 
the one that is of interest to me are the studies carried out in ovarian cancer using the 
siltuximab antibody.  
 33 
1.10 Siltuximab clinical trial conducted in the Centre for 
Cancer and Inflammation 
 
The clinical trial of siltuximab in ovarian cancer was based on several pre-clinical 
studies with cell lines, animal models and patient samples. These pre-clinical studies 
in my lab started by investigating the source of IL-6 in HGSC by staining patient 
tissue microarrays (TMAs), for IL-6 and its receptor. Significantly higher levels of 
IL-6 staining were present in the malignant cells compared to the stroma. This high 
level of IL-6 staining in malignant cells was also associated with shorter progression 
free and overall survival [35]. These results led the group to assess the therapeutic 
activity of an anti-human IL-6 antibody in human ovarian cancer. They combined 
pre-clinical and in silico experiments with a phase II clinical trial of siltuximab in 
ovarian cancer patients with platinum resistant disease.   
Out of the 18 platinum resistant ovarian cancer patients in the trial described above, 
one patient had partial response. Stable disease was achieved in eight of the patients 
for a period of time and from these patients, four received anti-IL-6 treatment for 6 
months or more. By the six-month time point all four of these patients had a 
significant reduction in the cytokine plasma levels of IL-6-regulated CCL2, CXCL12 
and VEGF. The study concluded that the mechanism of action of anti-IL-6 in ovarian 
cancer is by inhibition of autocrine production of cytokines and chemokines that has 
paracrine effects on angiogenesis via inhibition of VEGF, Jagged1 and interleukin-8 
(IL-8) and on the macrophage infiltrate via inhibition of chemoattractant CCL2 [35]. 
However, as the weeks progressed there was an increase in plasma cytokine levels, in 
particular IL-8, which correlated with disease progression. 
The above discussed pre-clinical studies from our lab on anti-IL-6 antibody treated 
HGSC xenografts showed a significant reduction in tumour vascular areas. 
Immunohistochemistry and qRT-PCR results showing decreased expression of an 
angiogenic factor, Jagged1, which is a ligand of Notch signalling and in this way 
forms part of the autocrine cytokine network in ovarian cancer [29]. High Jagged1 
levels were found in IL-6 secreting malignant cells and these levels were inhibited by 
the anti-IL-6 antibody siltuximab in xenograft models.  
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In the studies described above there was evidence that IL-6 might also be 
contributing to tumour angiogenesis. This observation was mainly based on the 
clinical and pre-clinical results, which showed decrease in VEGF levels in HGSC 
patients after treatment with siltuximab and the reduction in vascular areas with a 
decrease in Jagged1 expression noted in siltuximab treated HGSC xenografts. These 
data indicated a potential role of IL-6 in angiogenesis and led to the hypothesis to be 
investigated in this thesis.  
1.11 Angiogenesis 
 
Blood vessel formation is the first process in embryonic development and blood 
vessels form the largest network in our body. However, dysregulation of the vascular 
system can be a contributing factor to numerous malignant, ischemic and 
inflammatory disorders [68]. The formation of the vascular network either starts with 
an assembly process called vasculogenesis or through coordinated expansion of a pre-
existing vasculature. Vasculogenesis refers to the formation of blood vessels by 
differentiation of the mesodermal derived angioblast into endothelial cells, which then 
forms a primitive network [69]. In contrast angiogenesis refers to the sprouting of 
pre-existing endothelial cells and the subsequent stabilisation and maturation of the 
sprouts by pericytes [70]. Angiogenesis is co-ordinated by a series of morphogenic 
events, which ultimately leads to formation of an extensive vascular network. As 
shown in Figure 1.7, pro-angiogenic molecules can activate endothelial cells in pre-
existing vessels. These activated endothelial cells can then interact with pericytes to 
release proteases that degrade the basement membrane and extracellular matrix. This 
is followed by budding of activated endothelial cells migration and proliferation. 
Maturation proceeds with recruitment of pericytes to the endothelium [71].  
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Figure 1.7 Key stages in the process of angiogenesis.  
This process starts with a pro-angiogenic stimulus activating the endothelial cell, which then lead to 
release of proteases that degrade the extracellular matrix. This is followed by proliferation and 
migration of the endothelial cells and the subsequent stabilisation of the vessels by pericytes.  
Excessive or aberrant angiogenesis contributes to various disorders like cancer, 
arthritis, blindness, obesity and asthma. There are also several disorders caused by 
insufficient vessel growth such as hypertension, neurodegeneration, respiratory 
disorders and also heart and brain ischemia [68]. The long-held view in tumours was 
that the development of the vasculature was through angiogenic process from pre-
existing vessels. However, now studies have shown vasculogenesis as the contributor 
of at least 40% of the tumour vascularisation where the endothelial progenitor cells in 
the tumour are derived from the bone marrow [72].  
Other modes of vessel formation such as the intussusception, co-option and vascular 
mimicry are now being investigated. Intussusception is where the pre-existing vessels 
split into daughter vessels; in vessel co-option the tumour cells hijack the existing 
vasculature and migrate along the host vessels. Vessel co-option is mainly observed in 
highly vascularised tissues such as the brain, lung and liver. Vascular mimicry is 
normally seen in highly aggressive tumours where the tumours cells themselves form 
vessel like structures [73] 
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1.12 Angiogenesis and Cancer 
 
There have been several models developed to understand the process of 
tumourigenesis. These included exploring the initial events such as oncogene 
activation, which leads to genetic changes that affect the growth and transformation 
of certain cells [74, 75]. The studies revealed in addition to the genetic changes that 
occur during transformation, there is another important step required for the tumour 
progression, and this is the establishment of the tumour vasculature. This process has 
been named as the ‘angiogenic switch’ [76, 77]. This angiogenic switch can be turned 
on at different stages of tumour growth and is based on the nature and 
microenvironment of the tumour. The regulation of the angiogenic switch in tumours 
depends on the balance of the pro and anti-angiogenic agents. Stimuli such as 
hypoxia lead to increased expression of pro-angiogenic molecules such as VEGF, 
fibroblast growth factor (FGF), platelet derived growth factor (PDGF) and 
epidermal growth factor (EGF) that can lead to induction of the angiogenic switch 
[77]. 
Early studies showed that the tumour mass cannot exceed 1mm3 without a sufficient 
blood supply [78]. This is because, like normal cells, malignant cells require nutrients 
and oxygen in order to grow and these are supplied by new blood vessels [79]. 
However, there are several differences in the angiogenesis stimulated in tumours 
compared with normal physiological conditions. Physiological angiogenesis is a 
tightly regulated process involving a balanced level of pro and anti-angiogenic signals 
where the blood vessels rapidly mature and become stable [80]. However, in tumours 
the balance between pro and anti-angiogenic molecules is lost resulting in constant 
growth of new blood vessels.  
Tumour blood vessels also appear irregularly shaped, dilated and torturous. They are 
chaotic and leaky as compared to the organised vasculature seen in normal 
angiogenesis. There is also a defective coverage or very loose attachment of pericytes 
to the tumour endothelium [81, 82]. 
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Over the years, several molecules have been implicated as positive regulators of 
angiogenesis including FGF, transforming growth factor (TGF-α), (TGF-β), TNF-α, 
IL-8, angiopoietins and the Notch signalling pathway [83]. In depth investigation 
into the field of angiogenesis has identified VEGF as a key player in the regulation of 
angiogenesis in malignant diseases. The formation of new vessels involves highly co-
ordinated and sequential activation of various angiogenic pathways and among these, 
VEGF signalling often represents a critical rate limiting step in the process of 
angiogenesis [84].   
 
1.13 VEGF and its receptors 
 
The VEGF family consist of five members, VEGFA, B, C, D and placenta growth 
factor (PLGF) (Figure 1.8). There are three main VEGF receptors (VEGFR); 
VEGFR1, VEGFR2 and VEGFR3. There are also two co-receptors for VEGF, 
heparan sulfate proteoglycans (HSPG) and neuropilins, which lack the VEGF 
induced catalytic domain [84]. The VEGF ligands have different affinity for different 
VEGF receptors. For example the VEGFA, B and PLGF ligands bind to the 
VEGFR1 receptor, VEGFA and E bind to VEGFR2, and VEGFC and D bind to 
VEGFR3. VEGFC and D can also bind to VEGFR2 with lower affinity after it has 
undergone proteolytic processing. There are also some isoforms of VEGFA i.e. 
VEGFA 121, VEGFA 145, VEGFA 165, VEGFA 189 and VEGFA 206. These 
VEGFA isoforms are known to interact with the VEGF co-receptors HSPG and 
neuropilins [83].   
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Figure 1.8 VEGF receptors and their ligands.  
VEGFR1 and VEGFR2 functions via inducing angiogenesis and vasculogenesis and VEGFR3 plays a 
role in lymphangiogenesis.   
The main VEGF receptors i.e. VEGFR1 and VEGFR2 and the ligand VEGFA are 
regulated under low oxygen tension. HIF-1 is activated as a result of mutations in the 
Von-Hippel-Lindau (VHL) tumour suppressor gene, a key regulator of hypoxic 
conditions. VHL functions by negatively regulating the levels of VEGF and other 
hypoxic genes. Therefore, HIF is constitutively activated in conditions where the 
VHL gene is mutated and this has been shown to increase the mRNA levels of VEGF 
[84]. There are also several growth factors that have been implicated in the up-
regulation of VEGF mRNA and these include EGF, TGF-α, TGF-β, hepatocyte 
growth factor (HGF), insulin growth factor (IGF), FGF and PDGF[85].  
Binding of the ligand to VEGF receptors leads to homo or hetero dimerisation of the 
receptors. Once the receptors are dimerised, this leads to activation of the tyrosine 
kinase, resulting in autophosphorylation of the receptors [86]. The phosphorylated 
receptors can then recruit interacting proteins and this leads to the activation of 
 39 
downstream signalling pathways. The tyrosine kinase activity of the receptors can be 
inactivated by dephosphorylation of the receptors by tyrosine specific phosphatases. 
Downregulation of the receptor tyrosine kinase activity can also take place via 
proteasomal degradation or internalisation of the receptor and subsequent 
degradation in the lysosome [83].  
VEGFR1 or Flt-1 was the first receptor tyrosine kinase to be identified as a VEGF 
receptor. VEGFR1 mainly functions as a positive regulator of monocyte and 
macrophage migration and it is not particularly required for normal vascular 
development. During embryogenesis, VEGFR1 can also negatively regulate the 
function of VEGFR2 by acting as a trap for VEGFA and reducing its accessibility to 
VEGFR2. VEGFR1 can also crosstalk with VEGFR2 and negatively regulate the 
functions of VEGFR2 [87]. Activation of VEGFR1 by PLGF has shown to positively 
regulate VEGFR2 and this is thought to be as the result of the displacement of 
VEGFA from VEGFR1 [88].  
VEGFR2 or FLK-1 plays an important role in developmental angiogenesis and 
haematopoiesis. Mice lacking the VEGFR2 showed failure in forming organised 
blood vessels. Phosphorylation of these receptors results in activation of several 
pathways such as the PI3K (phosphatidylinositol-3 kinase), MAPK and the Src 
family. PI3K pathways activation is important in ensuring the pro-survival effects 
mediated by the VEGF signalling [85]. Downstream MAPK/ERK signalling is 
important in regulating the growth of the endothelial cells. VEGFR2 receptor 
activation increases the vascular permeability of the endothelial cells and this is 
mediated by the downstream activation of the p38 MAPK pathway. FAK (Focal 
adhesion kinase) is also implicated in the VEGF induced migration of the endothelial 
cells [87].  
VEGFR3 is involved in the establishment and maintenance of the lymphatic 
vasculature. This receptor can form homodimers or heterodimers with VEGFR2 and 
bind to VEGFC or D. VEGFR3 induced signalling can also be modulated by co-
receptors such as neuropilin-2. Neuropilin co-receptors were identified when studies 
into the VEGF binding sites on endothelial cell surface showed sites with distinct 
affinity and molecular mass from the two main VEGF receptors. Further 
investigations identified these receptors as neuropilin1, which are receptors that lack 
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the intrinsic catalytic activity and are known to be involved in neuronal guidance. 
When these neuropilin receptors are co-expressed with VEGFR2 they increase the 
binding affinity of the VEGFA isoform; 165 to the VEGFR2 thereby enhancing the 
downstream signal transduction [86].  
1.14 VEGF targeted therapies 
 
Understanding the role of VEGF in angiogenesis has led to the development of 
various VEGF targeted therapies. These agents include neutralising antibodies to 
VEGF or VEGFRs and inhibitors against the receptor tyrosine kinase that also target 
VEGFRs [89].  The first Food and Drug Administration (FDA) approval for anti-
angiogenic agents was based on a phase III clinical trial in metastatic colorectal 
patients where promising results were observed with the treatment of bevacizumab 
(monoclonal antibody against VEGFA) alone or in combination with chemotherapy 
[90].  This was followed by observation of increased overall survival in patients with 
advanced non-small cell lung cancer when bevacizumab was combined with standard 
chemotherapy [91]. This led to the use of anti-angiogenic agents in various tumour 
types as summarised in Table 2. 
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  VEGF targeting agent         Mode of Action           Cancer Types 
 
     Bevacizumab (Avastin) 
 
Monoclonal anti-VEGF   
antibody 
Breast, colorectal, non small cell 
lung, renal cell carcinoma, 
glioblastoma, ovarian, gastric, 
pancreatic and prostate cancer 
 
       Aflibercept (Zaltrap) 
 
Chimeric VEGF/PIGF 
neutralising receptor 
Colorectal, pancreatic, non small 
cell lung cancer 
 
      Sorafenib (Nexavar) 
 
Small- molecule VEGFR TKI 
Renal cell carcinoma, 
hepatocellular carcinoma, 
melanoma and non small cell 
lung cancer 
 
     Sunitinib (Sutent) 
 
Small- molecule VEGFR TKI 
Renal cell carcinoma, breast, 
hepatocelluar carcinoma, 
colorectal, pancreatic, non small 
cell lung cancer and prostate 
cancer 
    
    Pazopanib (Votrient) 
 
Small- molecule VEGFR TKI 
Renal cell carcinoma, non small 
cell lung cancer and soft tissue 
sarcomas 
     
    Vandetanib 
 
Small- molecule VEGFR TKI 
Non small cell lung cancer and 
medullary thyroid cancer 
    
     Vatalanib 
 
Small- molecule VEGFR TKI 
 
Colorectal cancer 
  
    Cediranib 
 
Small- molecule VEGFR TKI 
 
Colorectal, glioblastoma and 
ovarian cancer 
 
    Axitinib 
 
Small- molecule VEGFR TKI 
 
Renal cell carcinoma, pancreatic 
cancer 
Table 2 The list of anti-VEGF agents tested in various cancer types.  
Data adapted from [92] 
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Treatment with the majority of the above VEGF targeted therapies showed 
improvement in progression free survival in the various cancer types [92]. However, 
there are challenges or limitations with the use of these anti-angiogenic agents 
targeting VEGF signalling. Primarily, some cancers have shown resistance to these 
therapies and even in cases where an increase in progression free survival was 
observed it was by only a matter of few months [93]. There are several mechanisms 
involved in the induction of resistance to anti-VEGF therapies and these include up-
regulation of other pro-angiogenic molecules such as PIGF, FGF, IL-8 and IL-6, 
which will be discussed in more detail later. Some cancers also acquire resistance to 
VEGF therapies by switching their mode of vascularisation. For example, it has been 
shown in metastatic melanoma and lung cancer that the tumour cells are capable of 
growing in an angiogenesis independent manner by co-opting or growing around the 
pre-existing vessels upon treatment with bevacizumab [94]. Some studies have also 
shown DLL4, a Notch ligand involved in inducing mature stalk cell phenotype to 
mediate anti-VEGF therapy resistance. This as a result of the large vessels induced 
by the DLL4-Notch signalling, which are insensitive to VEGF therapy [95]. 
Neuropilin1 has also been shown to play a role in resistance by acting independently 
of VEGF [96]. Anti-VEGF therapy has also shown to increase metastasis by up-
regulation of c-MET in response to hypoxia [97]. Therefore, the combination of 
VEGF and c-MET inhibition has shown to reduce metastasis in pancreatic cancer 
[98, 99]. 
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1.15 The Notch signalling pathway 
 
As mentioned above, Notch signalling is another intrinsic signalling pathway that has 
also been shown to play a pivotal role in angiogenesis.  
Notch signalling is involved in regulating cell fate, differentiation and proliferation. 
Notch receptors and ligands are transmembrane proteins. The communication 
between a signal sending cell and a signal-receiving cell is mediated by cell-to-cell 
contact. In mammals, there are four Notch cell surface receptors; Notch1, 2, 3 and 4, 
and five transmembrane ligands i.e. Jagged1, Jagged2, Delta like ligand (DLL) 1, 3 
and 4 [100].  
Notch signalling requires a series of proteolytic cleaving processes. The first 
proteolytic step is carried out by a furin molecule, which produces a ligand binding 
Notch extracellular domain (NECD) and a single pass transmembrane signalling 
domain i.e. the Notch intracellular domain (NICD) [101]. Binding of DLL ligand to 
the NECD leads to activation of the pathway. This leads to the second preoteolytic 
cleavage step where the NECD is removed from the outer surface of the membrane 
by TNF-α converting enzyme (TACE). In the ligand-expressing cell, the NECD is 
internalised through endocytosis and thereby undergoes lysosomal degradation. 
Following this, γ-secretase cleaves the rest of the receptor in the Notch expressing 
cell, producing a transcriptionally active NICD, which then translocates to the 
nucleus and forms a complex with the coactivatorA (CoA) and the transcription 
factor CSL. This then leads to activation of basic helix–loop–helix proteins i.e. HES 
and HEY, which are transcriptional repressor genes (Figure 1.9). Activation of these 
proteins leads to Notch dependent cell fate determination: proliferation, apoptosis 
and differentiation [102, 103].  
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Figure 1.9 The Notch signalling pathway.  
Ligand binding to the Notch receptor via cell to cell contact leads to cleavage of the NECD by TACE, 
which is then endocytosed and degraded via the lysosome in the signal sending cell. Subsequently, the 
γ-secretase cleaves the NICD and translocates it to the nucleus where it forms a complex with the 
transcription factor CSL and the coactivators to activate HES and HEY repressor genes.  
 
Recently several studies have reported a non-canonical Notch signalling pathway, 
which is still not clearly understood [104]. This pathway is shown to be CSL 
independent and can be ligand dependent or independent. Various other ligands have 
been implicated in the induction of the Notch non-canonical pathway and these 
include Delta like 1 (DLK1), Delta and Notch like epidermal growth factor related 
receptor (DNER) and Jedi [101]. This non-canonical signalling interacts and 
activates pathways such as the NFκB, TGF-β and Wnt signalling [105]. Notch 
ligands can also inhibit the Notch signalling pathway. The activity of the Notch 
ligands can be regulated by post-transcriptional modifications or via cellular 
mechanisms such as endocytosis and proteolysis [106].  
The Notch signalling pathway is important for cell-cell communication especially in 
vascular formation, in neuronal function and development. It is also required for the 
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selection of endothelial tip and stalk cells in sprouting angiogenesis. The receptors 
Notch1 and Notch 4 and the ligands Jagged1, DLL1 and DLL4 are mainly 
expressed in the endothelial cells and are known to play an important role in vascular 
formation [107]. DLL4, which is induced by VEGF, is highly expressed in the 
vascular endothelial cells [102, 108]. Higher expression of DLL4 is found on the tip 
of the sprouting vessels and it binds to Notch1 and 4 receptors that are expressed on 
the stalk of the adjacent vessel. This interaction of DLL4 with the Notch receptor 
promotes the stalk cell phenotype enabling vascular integrity and tissue perfusion 
and this is mediated partially by reducing the expression of VEGFR2. The DLL4-
Notch interaction thereby maintains a balance between the tip cell and stalk cell, 
limiting the number of sprouting vessels [109]. Blocking DLL4-Notch signalling 
promoted excessive tip cell sprouting and angiogenesis. The vessels formed as a result 
of DLL4 inhibition were abnormal and poorly perfused with decreased pericyte 
coverage resulting in increased hypoxia [101].  
Jagged1 antagonises DLL4, thereby blocking the positive Notch-DLL4 interaction 
leading to more of a tip phenotype. This is mediated through the fringe family 
members, which carry out post-transcriptional modifications on the Notch receptors. 
Fringe glycosylated Notch receptors shows strong activation of downstream targets 
HEY1 by DLL4 [108]. However, Jagged1, which normally has lower binding 
affinity than DLL4 to Notch receptors, works as an antagonist and can block DLL4-
Notch interactions in fringe expressing cells [109]. There is an oscillatory effect 
reported with the regulation of the Notch signalling in the presence of VEGF. VEGF 
interaction in endothelial cells leads to induction of DLL4, which then binds to the 
Notch receptor resulting in the release of the NCID to the nucleus. This induces 
expression of HEY gene and the fringe gene. Fringe then glycosylates the Notch 
receptor thereby enhancing Notch-DLL4 interaction and decreasing Notch 
signalling in the presence of Jagged1 [110]. 
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1.16 Role of Notch in tumorigenesis 
 
The first evidence showing the involvement of Notch in cancer came from studies 
carried out in T-Acute Lymphoblastic Leukaemia (ALL), where an activating 
Notch1 mutation was found in 56% of the T-ALL patients [100].  Notch drives 
tumorigenesis in T-ALL by promoting cell-cycle progression and inhibiting apoptosis 
[111]. MYC, a driver of cell cycle progression, is also regulated by Notch in T-ALL 
(33, 34,23). In Acute Myeloid Leukaemia (AML), high levels of Notch1, Jagged1 
and DLL1 were each found to be independent factors associated with poor prognosis 
[112].  
Increased expression of Notch1 and Jagged1 is linked to poor prognosis in breast 
cancer. A recent study showed an up-regulation in the levels of IL-6 by the non-
canonical Notch signalling in breast cancer cells. This Notch mediated up-regulation 
of IL-6 was controlled by the NFκB signalling cascade and by P53. This was shown 
to be CSL independent and resulted in the reduction of HEY expression [113].  
Notch3 is overexpressed in 40% of the Non Small Cell Lung Cancer (NSCLC) 
patients and is involved in inhibiting apoptosis by activation of the EGFR/MAPK 
pathway [114]. High expression of Notch1 correlated with poor survival in lung 
adenocarcinoma patients and suggested inhibiting Notch1 to be a useful strategy for 
treating these patients [115].  
In glioma patients, screening for overexpressed genes showed high levels of Notch1, 
DLL1 and Jagged1 [116]. Knockdown of these genes in mice resulted in increased 
apoptosis of glioma cells and increased survival of mice, indicating that Notch 
signalling drives glioma cell growth. Notch1 also correlated with glioma progression 
and poor outcome in patients [117].  
Notch signalling plays a major role in prostate cancer development and metastasis. A 
study that included 154 prostate cancer samples showed overexpression of Jagged1 
and Notch1 in metastatic prostate cancer patients compared to localised and benign 
tumours [118]. Knockdown of Notch1 inhibits proliferation and invasion of prostate 
cancer cells [119].  
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The Cancer Genome Atlas (TCGA) published data on most common abnormalities in 
489 HGSC patients and the results showed dysregulated Notch signalling in 22% of 
the samples [8].  Studies in ovarian cancer stem cells (CSC) showed Notch3 to play a 
major role in chemoresistance to platinum based therapies [120]. Also, as previously 
reported, studies from my lab have shown Jagged1 to be involved in an autocrine 
cytokine network in ovarian cancer cells. Notch related drug resistance is also seen in 
colon cancer after treatment with oxaliplatin via activation of survival pathways such 
as PI3K/AKT [103].  
Notch signalling is a ‘double-edged sword’ because Notch pathway members not only 
function as oncogenes but it can also act as tumour suppressors in certain cancer 
types [121]. For example, loss of Notch1 in skin epithelial cells leads to improper 
epidermal formation and impairs skin barrier integrity, which results in inflammation 
and tumorigenesis. Cervix development is also regulated by Notch and both an 
upregulation or downregulation of Notch have been associated with cervical cancer. 
Notch signalling has also been shown to activate p53 in some cervical cancer studies 
leading to growth arrest [103]. 
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1.17 Targeting Notch in Cancer 
 
Notch pathway targeting agents are in clinical development in many types of cancers 
(Table 3). For instance, γ-secretase inhibitors (GSI) for gain of function of Notch are 
being tested as possible anti-cancer agents [122]. Pre-clinical studies in lung, breast 
and pancreatic cancer have shown GSIs to suppress tumour growth [123-125]. 
However, there were numerous side effects witnessed in the in vivo studies with GSI 
treatment. These side effects included alteration of intestinal architecture, increased 
mucin secretion, epithelial erosion, leucocyte infiltration and abnormal changes in 
thymus and spleen [126]. At present, there are over 40 clinical trials either in 
progress or recently completed in T-ALL, breast, colorectal, lung, prostate and 
pancreatic cancer with GSI inhibitors alone or in combination with other drugs. A 
phase II clinical trial in metastatic colon cancer using a GSI inhibitor increased PFS 
by 1.8 months, indicating GSI single agent therapy is not effective [127].  
Due to the high level of toxicity observed with the GSI inhibitors, antibodies against 
Notch receptors or ligands are now being developed. This approach is useful in cases 
like T-ALL where specific receptors like Notch1 are implicated in tumour growth. 
Preliminary in vivo studies with these specific Notch1/2 inhibitors show promising 
results, without causing major side effects as witnessed with the GSI treatment [128]. 
Similarly, pre-clinical in vitro and in vivo studies with antibodies against Notch ligands 
like DLL4 are being tested in various models. DLL4 inhibition led to formation of 
non-functional vessels with poor oxygen and nutrient supply [129]. A recent study 
using an anti-DLL4 antibody, MEDI0639 in an in vivo matrigel plug assay with 
human endothelial cells, resulted in excessive angiogenic sprouting with very poor α-
smooth muscle cell coverage around the vessels, further indicating non-functional 
vessel formation [130]. MEDI0639 is currently being tested in a phase I trial in 
advanced solid cancers to test its safety and tolerability. Other DLL4 targeting 
antibodies are also being tested in combination with ionising radiation in colorectal 
cancer. The combination therapy resulted in impaired tumour growth by promoting 
non-functional tumour angiogenesis and extensive tumour necrosis [131].  
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Notch targeting Agents 
  
    Cancer type tested 
 
Developmental Phase 
    
     Anti-Notch1 mAb 
 
Breast cancer, colon cancer, 
T-cell leukemia, anaplastic 
carcinoma 
  
   Pre-clinical studies 
     
    Anti-Notch2 mAb 
 
Breast cancer, colon cancer, 
anaplastic carcinoma 
 
    Pre-clinical studies 
 
    Anti-Notch2/3 mAb 
 
  Solid tumours 
 
       Phase 1 trial 
 
    Anti-DLL4 mAb 
Colorectal cancer, small cell 
lung cancer, pancreatic 
cancer and other solid 
tumours 
        
        Phase 1 trial 
 
  Soluble forms of Notch1, 
DLL1 and Jagged1 
 
Endothelial cells  
 
Pre-clinical studies 
 
             
       γ-secretase inhibitors 
 
Breast cancer, prostate 
cancer, non small cell lung 
cancer, pancreatic cancer, 
brain tumours, colorectal 
cancer, melanoma, T-cell 
leukemia 
 
Phase 1 clinical trial 
Table 3 List of Notch signalling targeting agents in various cancer types.  
Data adapted from [132]. 
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1.18 Pericytes 
  
To maintain functional angiogenesis the vascular structure needs to be stabilised by 
supporting cells. These supporting cells are called pericytes; contractile cells that 
wrap around the endothelial cells and stabilise the vasculature, regulating micro-
vascular blood flow [133]. 
Pericytes are embedded within the vascular basement membrane and they are known 
to play a major role in vascular development and homeostasis. Pericytes found on the 
blood microvessels make focal contact with the endothelium and extend primary 
cytoplasmic processes along the surface of the endothelium [134]. 
The interaction between the endothelial cell and the pericyte helps in the regulation 
of the vascular basement membrane. In most areas, endothelial cells and pericytes are 
separated by the vascular basement membrane. However, the two cell types come in 
contact at interfaces where there are holes in the endothelium. There are up to 1000 
different contact points that have been described for a single endothelial cell [135]. 
Among these are areas called the peg pocket contacts in which the finger like 
cytoplasmic projections of the pericytes are inserted into the endothelial 
invaginations. Then there are adhesion plaques, which are areas that anchor the 
pericyte to the endothelial cell via N-cadherin connections. There are also direct 
connections such as gap junctions between the endothelial cell and pericyte that 
enable exchange of ions and small molecules [135]. 
The central nervous system (CNS) has the highest pericyte coverage around the 
microvessels. The exact role of these pericytes in the CNS is still not clear, however 
they are believed to play a role in the formation of the blood brain barrier [136]. In 
vitro co-culture studies have suggested that pericytes can improve blood brain barrier 
function [137]. Pericytes also function as sensors of hypoxia and it can mediate 
adaptive responses to protect the neurons of the CNS. Another tissue that is 
abundant with pericyte coverage is the retina. This is due to its high level of 
metabolic demands and this is also the most sensitive site for partial loss of pericytes 
[136].  
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There are several molecular markers used to identify pericytes and they include α-
SMA, NG-2, desmin, platelet derived growth factor-beta (PDGFR-β), 
aminopeptidase A/N and RGS5. Since none of these markers are absolutely specific 
for pericytes, more than one marker is used or pericytes are identified by their 
location in relation to the endothelial cells [134].  
1.19 Endothelial cell-pericyte interactions 
 
As stated above, endothelial-pericyte communication is critical for blood vessel 
formation and function [135]. This interaction controls growth signals that inhibit 
endothelial proliferation. During vascular formation, pericytes are important for 
vascular pruning and for controlling the number of functional vessels, thereby 
enhancing tissue perfusion [136].  
There are a host of different molecules that control the endothelial-pericyte 
interactions, regulating each step such as pericyte recruitment, attachment and 
detachment. TGF-β contributes to the differentiation of precursor cells into pericytes. 
Various studies have shown the importance of TGF-β in the de novo induction of 
vascular smooth muscle cells and defective TGF-β signalling leads to embryonic 
lethality [133]. TGF-β inhibits endothelial cells proliferation and migration. 
Inhibition of this pathway has shown to shift the balance from differentiation to 
endothelial proliferation thus resulting in more dilated and irregularly shaped vessels 
[133].  
PDGF-B/PDGFRβ signalling plays a major role in endothelial-pericyte interactions. 
PDGF-B secreted from the endothelial cells binds to the pericyte PDGFRβ tyrosine 
kinase receptor. This interaction helps in the proliferation, migration and subsequent 
recruitment of pericytes to the newly formed vessels. Knockout for the PDGF 
ligand/receptor causes vascular dysfunction as a result of defective pericytes, which 
leads to endothelial hyperplasia and abnormal endothelial junctions [136].  
Angiopoietin/Tie2 signalling is also implicated in endothelial-pericyte interactions. 
The two main ligands of this signalling pathway are Angiopoietin1 and 2 (Ang1 and 
Ang2).  Ang1 is produced by the pericytes, Ang2 is expressed by endothelial cells and 
is located at the leading end of the proliferating vessels. Both these ligands bind to the 
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Tie2 receptors expressed on the endothelial cell and play a role in endothelial 
sprouting, vessel wall remodelling and pericyte recruitment (56). Loss and gain of 
function studies in Ang/Tie2 signalling have shown this pathway to be the gatekeeper 
of quiescent endothelial cell phenotype [133].  Studies in mice have shown the Ang1-
Tie2 signalling to play a critical role in vessel maturation and stabilisation. Knock out 
of Ang1 or Tie2 in mice resulted in defective angiogenesis with poorly organised 
basement membrane [136]. The vessels formed in these mice also showed poor 
coverage and detachment of pericytes. Overexpression studies with Ang1 led to 
formation of a stabilised vasculature with leakage resistant vessels. Recombinant 
Ang1 was also able to partially restore the pericyte coverage and thereby rescue the 
vascular defects in the retina [136].  
Ang2 acts as an antagonist of Ang1 and blocks the Ang1/Tie2 signalling resulting in 
dissociation of pericytes from vessels resulting in reduced pericyte coverage and 
destabilised vessels (Figure 1.10). Ang2 overexpression phenotype has shown to 
resemble that of the Ang1 or Tie2 knockout. Therefore, Ang1 and Ang2 expressed on 
different cell types have opposing effects on angiogenesis, with Ang1/Tie2 paracrine 
loop resulting in vessel stabilisation phenotype and Ang2/Tie2 autocrine loop in the 
endothelial cells resulting in a vessel destabilising phenotype [138].  
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Figure 1.10 Angiopoietin/Tie signalling between the endothelial cells and 
pericytes.  
Ang1 from the pericyte binds to the Tie receptor on the endothelial cell helping in the stabilisation of 
vessels. Ang2 released from the endothelial cell can act as an Ang1 antagonist and binds to Tie 
receptors on the endothelial cell resulting in pericyte loss.  
N-cadherins found in the interface between endothelial cells and pericytes also play a 
major role in adhesion of pericytes to endothelial cells [139]. N-cadherins are not 
important for vasculogenesis, proliferation or migration of vessels but N-cadherin 
deficiency leads to impairment of pericytes covering the endothelium [140]. Then 
there are also other factors such as neural cell adhesion molecule (NCAM), vascular 
cell adhesion molecule (VCAM), EphrinB2 and integrin signalling that are involved 
in vessel maturation by regulating the adhesion of pericytes to endothelial cells. 
Notch signalling is also implicated in vascular smooth muscle cell differentiation. 
Activation of Notch3 in the smooth muscle cells by Jagged1 initiates the formation of 
smooth muscle cells around the developing vessels [141]. In contrast, there are 
several findings showing positive correlation of the Notch ligand DLL4 with α-SMA 
staining. For example, a study carried out in bladder cancer showed that 98.7% of 
DLL4 positive tumour vessels were covered with α-SMA as opposed to 64.5% of 
DLL4 negative tumour vessels [142]. This finding was also supported by loss of 
function of DLL4 studies, which resulted in increased vascular proliferation with 
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decreased vessel maturation. The newly formed vessels showed decreased vascular 
lumen with defective pericyte coverage and reduced tissue perfusion [143].  
1.20 Pericyte inhibitors in cancer treatment 
 
As previously mentioned, compared to the normal tissue vasculature, tumour vessels 
are structurally and functionally abnormal. They are characterised by disorganised 
and highly dysfunctional vessels with leaky endothelial cell layer and loosely 
connected or abnormal pericyte coverage. Therefore, studies into understanding the 
role of pericytes in tumour vasculature have been explored. 
Targeting the pericyte in tumour angiogenesis became of interest after anti-VEGF 
therapy resistance studies showed up-regulation of alternative pro-angiogenic 
pathways such as PDGF-B/PDGFRβ signalling. Vessels, which are sensitive to 
VEGF therapies, are mainly composed of immature vessels lacking pericyte coverage 
and the ones, which are resistant to VEGF therapies tend to be large mature vessels 
with good pericyte coverage [144]. Therefore, various strategies such as inhibiting 
especially the PDGF-B/PDGFRβ and Ang/Tie signalling are being tested pre-
clinically and clinically to target the pericyte population that stabilises the tumour 
vasculature.  
PDGF receptor kinase inhibitors such as imatinib, sunitinib, sorafenib, pazopanib 
and nilotanib are now tested in various cancer models. However, none of these 
inhibitors are specific and they also target other pathways such as c-kit, VEGF and 
FGF signalling. Imatinib treatment in tumour models resulted in reduced tumour 
interstitial fluid pressure thereby increasing the uptake of tumour seeking radio 
labelled antibody. This improved antibody uptake as a result of reduced interstitial 
fluid was identified as the primary reason for growth arrest in a colorectal cancer 
model [145]. Therefore, pre-clinical studies with PDGFRβ inhibitors in combination 
with chemo or radiotherapy displayed some beneficial effects. Similarly, PDGFRβ 
inhibition along with anti-VEGF therapy in the RIP Tag2 model of pancreatic cancer 
resulted in 80% reduction in pericyte numbers within the tumours. This correlated 
with increased cell death in endothelial and tumour cells thereby decreasing tumour 
growth [146]. However, clinical trial in renal cancer after treatment with VEGF and 
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PDGFR inhibitors showed no therapeutic benefit in the combination therapy group 
as compared to the single agent treatment with VEGF inhibition [147, 148]. 
Targeting Ang/Tie2 signalling in VEGF therapy resistant tumours is also considered 
an effective way to destabilise vessels by disrupting pericyte-endothelial cell 
interaction. Trebananib (AMG 386), a peptide tumour protein that interferes with 
Ang/Tie2 signalling was tested in combination with paclitaxel in a Phase II trial for 
patients with recurrent ovarian cancer. Even though the study did not result in 
statistically significant increase in progression free survival, the data suggested 
evidence of anti-tumour activity [149]. Phase III studies in recurrent ovarian cancer 
and Phase II studies in breast, colorectal, kidney, stomach and liver cancer are now 
being conducted [150]. 
However there have been studies showing no improvement in survival with the 
combination treatment of VEGF and pericyte inhibition. For example, a study 
carried out in T241 fibrosarcoma, B16 melanoma and Lewis lung carcinoma used a 
more specific pericyte depleting method using PDGFRβ deficient mice rather than a 
tyrosine kinase inhibitor. The study showed that pericyte depleted tumours and 
control tumours both showed same sensitivity to G6-31 VEGFA antibody. There was 
no additional decrease in tumour growth or vascular density in the pericyte deficient 
tumours as compared to the control tumours after treatment with the anti- VEGFA 
antibody [151].  
Also some of these studies, especially the ones using the PDGFRβ inhibitor did not 
assess the effect of the inhibitor on metastasis. This is important because increasingly 
pericytes are being reported as the gatekeepers of tumour cell metastasis [138]. 
Studies in PDGFRβ deficient Rip1Tag2 mice with defective pericytes showed 
development of metastases in distant organs and local lymph nodes. This suggested 
that pericyte loss on tumour vessels could lead to escape and spread of tumour cells.  
Another critical development in the benefits of restoring stabilised vasculature rather 
than disrupting the pericyte coverage came from Ang2 targeted studies in cancer 
treatment (Table 4). Ang2, as previously mentioned, is an antagonist of the Ang1/Tie 
signalling, and leads to detachment of pericytes from tumour vessels. Ang2 targeting 
approach was undertaken after studies in breast, gastric and metastatic melanoma 
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showed Ang2 to correlate with lymph node metastasis in patients [150]. Also, in 
prostate cancer studies there was higher expression of Ang2 staining in the malignant 
and metastatic tissue compared to Ang1, which was strongly expressed in non-
malignant tissue [152].  
More recent studies using recombinant humanised monoclonal antibody against 
Ang2 have shown promise in breast and colon cancer. There was a 50% reduction in 
Ang2 protein levels in tumours with a significant decrease in vessel number, density 
and pro inflammatory Tie2+ expressing monocytes, which contribute to tumour 
progression [153]. Ang2 blocking also reduced tumour vasculature and inhibited 
progression of late stage metastatic mammary carcinomas and Rip1-Tag2 tumours 
[154].  
Ang2 is also one of the main factors involved in inducing resistance to anti-angiogenic 
therapies [155]. Combination studies using Ang2 and VEGF blocking agents have 
been effective in targeting various tumours. This idea of targeting Ang2 and VEGF 
came from early studies carried out in advanced colorectal and epithelial ovarian 
cancer, where combined Ang2 and VEGF expression correlated with worse 
prognosis than either alone [156, 157]. Therefore, studies carried out with Ang2 and 
VEGF combination therapy in various tumour models have shown increased anti-
tumour activity in the combination group as a result of potent inhibition of 
angiogenesis and tumour growth [158]. Ang2 inhibition has not only shown to inhibit 
tumour growth and tumour cell dissemination and metastasis but also suppressed the 
growth of established metastases [154] 
The Ang2 receptor Tie2 is also weakly expressed by some circulating monocytes and 
is upregulated upon recruitment into tumours and differentiation into a subset of 
perivascular macrophages called Tie2 expressing macrophages (TEMs). These 
TEMs are similar to M2 polarised macrophages and they respond to Ang2 
stimulation and drive tumour angiogenesis. They have also been shown to promote 
vascular regrowth following anti-angiogenic therapy induced vascular damage. 
Blocking Ang2 impedes the interaction of TEMs with blood vessels due to failure to 
upregulate Tie2. Therefore, inhibiting Ang2 cannot only inhibit tumour metastasis 
directly but also indirectly inhibit TEMs [154]. Hence, the combination therapy of 
VEGF and Ang2 inhibitors are of great interest now.  
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Table 4 List of Ang/Tie2 targeting agents tested in different phases of clinical 
trials in tumours.  
     (Data adapted from [150]). 
 
       Agents 
           
            Targets 
 
                    Tumour 
 
 
AMG 386 
 
 
Ang1, Ang2 
 
Tested in Phase I to III trials in ovarian, breast, 
gastric, hepatocellular and renal cell carcinoma, 
endometrioid, colorectal cancer and 
glioblastoma 
 
CVX-060 
 
Ang2 
 
Tested in Phase Ib/II trial in renal cell carcinoma 
 
CVX-241 
 
Ang2, VEGFA 
 
Tested in Phase I trial in ovarian and primary 
peritoneal disease 
 
MEDI-3617 
 
Ang2 
 
Tested in Phase I trial in advanced solid tumours 
 
REGN910 
 
Ang2 
 
Tested in Phase I trial in advanced solid tumours 
 
AMG-780 
 
Ang2 
 
Tested in Phase I trial in advanced solid tumours 
 
CEP-1198 
 
Tie2, VEGFR 
 
Tested in Phase I trial in advanced solid tumours 
 
MGCD265 
 
Tie2, c-MET, 
VEGFR1-3 
 
Tested in Phase I/II trials in advanced 
malignancies, non small cell lung cancer 
 
Regorafenib 
 
Tie2, VEGFR2 
 
Tested in Phase III trials in gastrointestinal and 
renal cell carcinoma 
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1.21 IL-6 as an angiogenic factor in Cancer 
 
As previously described, IL-6 and its downstream signalling have also been 
implicated in resistance to anti-angiogenic therapies [159, 160]. However, in depth 
investigation into the role of IL-6 as an angiogenic factor in cancer have not yet been 
explored in detail.  
The secretion of IL-6 from endothelial cells was observed a long time ago and over 
the years more studies have also supported the existence of IL-6Rα on endothelial 
cells [47, 161, 162]. These observations initiated investigations into the role of IL-6 in 
angiogenesis. This has led to studies showing the positive regulation of endothelial 
progenitor cell proliferation and migration by IL-6 in a dose dependent manner [163, 
164]  
Cohen et al investigated the effects of IL-6 on various tumour cell lines and found that 
IL-6 treatment led to upregulation of VEGF mRNA levels in those cells [165]. Since 
then, there have been several studies carried out in various cancers further 
demonstrating the link between IL-6 and VEGF via the common transcription factor 
NFκB [166]. IL-6 drives HIF-1α production and HIF-1α is a key regulator of 
VEGF, which further suggests the link between IL-6 and VEGF [167]. 
IL-6 induced expression and regulation of VEGF in tumours has been demonstrated 
in various pre-clinical and clinical studies [168-171]. For example, IL-6 is considered 
as a target in gliobastoma, where it is shown to drive tumour cell invasion and 
angiogenesis. High levels of IL-6 and VEGF have been reported in gliobastoma 
patients and monotherapy with either agent has not been that effective. Elevated 
levels of IL-6 were also found in glioma patients who failed bevacizumab therapy 
[159]. Therefore combination of IL-6 and VEGF inhibition has become a potential 
strategy in treating glioma patients.  
Similarly, IL-6 was also shown to play a role in the development of resistance in 
sunitinib treated advanced renal cell carcinoma patients [172]. Elevated levels of IL-6 
were also observed throughout the course of sunitinib treatment in hepatocellular 
carcinoma patients, which further supports, the role of IL-6 in relapse mechanism to 
anti-angiogenic therapies [160]. 
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IL-6 has also been implicated in the regulation of other angiogenic signalling 
pathways, such as the Notch signalling pathway which is involved in numerous 
aspects of tumour angiogenesis including endothelial tip sprouting and vessel 
maturation [109]. The link between IL-6 and Notch was first reported in a study 
carried out by Sansone et al, in ductal breast carcinoma. According to the study IL-6 
regulated a Notch-3 dependent signalling via Jagged1, which promoted self-renewal, 
hypoxia survival and invasive potential of normal and tumour mammospheres. 
Administration of anti-IL-6 to tumour mammospheres for 24 hours resulted in down 
regulation of Notch-3 mRNA and administration of IL-6 yielded Notch-3 mRNA. 
The data suggested that IL-6 might trigger a potential autocrine/paracrine Notch-
3/Jagged1 loop to boost stem/progenitor cell self-renewal in the mammary gland 
[62]. Also studies from my lab have shown the decrease in expression of Jagged1 
with a normalization and reduction in tumour vasculature after the treatment with an 
anti-IL-6 antibody [35]. 
Collectively, the involvement of IL-6 in other angiogenic signalling pathways along 
with the observations from various cancer models, including the findings from the 
HGSC clinical trial described above, indicate that IL-6 secreted from the malignant 
cell may effect tumour angiogenesis. This in conjunction with the results from the 
clinical studies showing IL-6 mediated anti-angiogenic therapy resistance and 
metastasis, suggests the possibility that IL-6 can act as driver of tumour angiogenesis 
in the absence of VEGF.  Therefore, the hypothesis underlying the research in this 
study is ‘IL-6 drives aberrant angiogenesis independent of VEGF signalling’. 
In order to investigate this hypothesis the objectives of my study are as follows: 
1. Establish experimental models to study the effects of IL-6 on normal 
endothelial cell angiogenesis. 
 
2. Investigate the mechanisms of action of IL-6 on endothelial cells 
 
3. Study the effects of IL-6 as an angiogenic factor in ovarian cancer  
 
 
 60 
2 Materials and Methods 
 
In the experiments described in this thesis, I have used VEGFA (VEGF), as this is 
the most commonly identified ligand in tumours.  
 
2.1  Aortic Ring Assay 
 
The aortic rings cultured in collagen with appropriate medium and angiogenic factors 
give rise to microvessel growth surrounded by pericytes. Angiogenic activators and 
inhibitors can be tested for their efficiency in inducing or inhibiting vessel growth 
using this model.  
2.1.1 Extraction of Aorta 
 
C57Black6 mice from 8 to 12 weeks old or Wistar rats weighing between 180-200g 
were used for this assay. The dead mouse/rat was first surface sterilised using 70% 
ethanol and then placed back down on a dissecting board in a laminar flow tissue 
culture hood. The skin was then cut from tail to neck. Once the sternum was located, 
the ribcage was cut along the middle and the heart and lungs were removed to expose 
the aorta, which is a deep red line running down the side of cavity. The aorta was 
then detached from the spine using a closed pair of forceps and closed scissors. 1cm 
of aorta was then cut and placed in a dish with PBS. 
2.1.2 Cleaning 
 
Under the dissecting microscope the extraneous fat, tissue and branching vessels 
were removed with forceps and a scalpel. Using a 27-G syringe fixed to a 1ml needle, 
the blood was flushed out of the aorta with OptiMEM (Gibco, cat. no. 51985-026). 
The aorta was then cut into small 0.5mm size rings and was transferred to a 10cm 
petri dish with 5ml of serum free OptiMEM + 1X penstrap (PS; PAA, P11-010, 
100X). The rings were then incubated overnight at 37°C and 5% CO2. 
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2.1.3 Embedding 
 
The collagen mixture was prepared on ice. One-tenth volume of sterile 10X DMEM 
(Gibco, cat. no. 12800-017) was added to sterile water. Collagen (Millipore, cat. no. 
08-115) was then added to a final concentration of 1mg/ml and thoroughly mixed. To 
this solution, 5N NaOH was added dropwise until the collagen mixture turned pink. 
50µl of the collagen solution was distributed in each well of a 96 well plate. The 
serum starved rings were taken out of the incubator and dried before being placed 
onto the collagen containing wells. Once the rings were embedded in collagen, the 
plate was left to set for 1 hour at 37°C and 5% CO2. The rings were then fed with 
150µl of Optimen containing 1%FCS for the control. The concentration used for the 
other reagents are as follows 30ng/ml VEGF, 50ng/ml hIL-6, 30ng/ml mIL-6, 
10ng/ml rIL-6 and 10nM VEGFRi. The medium was changed every 2 to 3 days. The 
rings were imaged once a week using phase contrast microscopy.  
2.1.4 Staining of Aortic rings 
 
The rat and mouse aortic rings we respectively cultured for 1 and 2 weeks before the 
staining. The rings were washed with PBS, fixed in 4% formaldehyde for 20 minutes. 
The wells were then washed once in PBS and the rings were permeabilised with 0.5% 
Triton X-100 in PBS for 30 minutes, before being washed twice in PBS. 100µl of BS-
1 Lectin FITC (1 mg/ml; Sigma, cat. no. L9381/L5264) (1:200 in PBS) and anti-
actin, α-SMA Cy3 (Sigma, cat. no. C6198) (1:500) was added and incubated 
overnight at 4ºC. In case of the IL-6Rα staining on aortic rings, 100µl of the 
unconjugated (1 in 200) IL-6Rα antibody was left overnight at 4ºC. The following 
day the rings were washed with PBS and incubated with goat anti-rabbit Alexa 488 
antibody (Life Technologies, A-11034) for 2 hours at room temperature. The plates 
were washed twice in PBS and the rings were removed from the 96 well plate, using 
a syringe needle, placed on a microscope slide and mounted with Prolong Gold DAPI 
containing medium (Invitrogen, cat. no. P36931). The slides were left to dry and 
imaged using confocal microscopy.  
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2.1.5 Quantification of number, length of sprouts and pericyte 
coverage 
 
The effect of medium, VEGF and IL6 on the sprout development was assessed by 
quantification of the average number of sprouts per condition. The length of sprouts 
was quantified using ImageJ software by drawing radial lines from the base of the 
aortic ring to the tip of the sprouting new vessel. Each measurement was then saved 
and the average length per aorta was calculated for each condition.  Pericytes were 
quantified 250microns from the tip of the aortic ring vessel to avoid false positive 
quantification of activated fibroblast, which are normally found at the stalk of the 
vessel. 
 
2.2 Tissue culture 
 
2.2.1 Mouse Lung Endothelial cell line (MLEC)  
 
MLEC, kindly given by Prof Kairbaan Hodivala-dilke, were used for most of the in 
vitro studies. Endothelial cells, immortalised with a temperature sensitive oncogene, 
were isolated as previously described [173]. This protocol used wild type mice 
crossed with H-2Kb-tsA58 (immorto gene) mice that express a temperature sensitive 
simian virus. The isolation was carried out by digesting the mouse lungs with 
collagenase. The digested cells were then further disaggregated in order to produce a 
single cell suspension. Since the initial suspension of cells contain a mixed population 
of endothelial cells, macrophages and fibroblasts, they were then subjected to a series 
of negative and positive sorts resulting in a >90% pure population of endothelial cells 
[174].  
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The MLEC medium was prepared as described below: 
- 500ml of DMEM (Life Technologies, 10567-014) was mixed with 500ml 
Hams-F12 nutrient mix (Life Technologies, 31765-027) 
- 50mg Heparin (Sigma-Aldrich, H3149) was dissolved in the above prepared 
medium 
- 10 ml of 1X Pen-Strep (PS; PAA, P11-010, 100X) and 10ml of 200mM 
glutamine was added to the medium and then filtered with a 0.2 µm disposable 
bottle top filter.  
- 25mg of endothelial mitogen (AbD seroTec, 4110-5004) and 100ml of FCS 
(FBS; PAA, A15-104) was added to the filtered medium and stored at 4ºC. 
 
2.2.2 IGROV-1 
 
The human ovarian cancer cell line (IGROV-1) was seeded in endotoxin free RPMI-
1640 with L-Glutamine (PAA, E15-840), 10% Fetal Bovine Serum (FBS; PAA, A15-
104) and 1X Penicillin/Streptomycin (PS; PAA, P11-010, 100X), and grown under 
standard conditions (37°C, 5% CO2). Cells were passaged every 2-3 days after 
washing in Dulbecco’s PBS without Ca & Mg, (PAA, H15-002) and detached with 
0.1%/0.04% Trypsin-EDTA in PBS, (PAA, L11-003, 0.5%/0.2%). The cell line was 
regularly checked for mycoplasma infection. 
 
2.3 Proliferation Assay 
 
70,000 MLEC cells were seeded in a 24 well plate. The following day cells were 
treated with either 50 or 100ng/ml of VEGF, hIL-6 or mIL-6. The plate was then 
incubated for 72 hours at 37°C and 5% CO2. After incubation, the cells were 
trypsinised and counted using the Vi-cell counter (Beckman Coutler). Each condition 
was repeated in triplicate.  
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2.4 Scratch Assay 
 
MLEC cells were cultured to a confluent monolayer in a 12 well plate. A scratch was 
made in the middle of each well using a p20 tip. The dislodged cells were then 
removed and cells were washed with PBS. The cells were then treated with 100ng/ml 
of VEGF or 100ng/ml of human/mouse IL-6 in serum free MLEC medium and 
placed under a time-lapse microscope. Images of the ‘wound’ were taken every hour 
for 16 hours. The wound closure percentage was determined by comparing the 
surface area of the defined wound area at 0 and 16 hours (% closure = migrated cell 
surface area / total surface area X 100). 
2.5 Staining of MLEC 
 
2x105 MLEC cells were plated on a coverslip in a 12 well plate. The coverslips were 
fixed with 4% formaldehyde for 30 min and washed with PBS (3 times for 5 min 
each). Following fixation the cells were permeablised with 0.1% Triton for 20 min 
and washed again in PBS. The cover slips were incubated with (1 in 200) rabbit IgG 
(R&D) or IL-6Rα antibody (1 in 200) (Santa Cruz C-20, Sc-661) overnight at 4°C. 
The following day the cover slips were incubated with secondary (1:2000) goat anti-
rabbit Alexa 488 (Life Technologies, A-11034) for 2 hours at room temperature and 
then mounted on slides with Prolong Gold DAPI containing medium (Invitrogen, 
P36931). The images were taken using confocal microscopy. The same was repeated 
for pSTAT3 (1 in 100)(Cell signalling, D3A7) staining after treatment of the 
coverslips for 24 hours with human or mouse IL-6 (30ng/ml).  
2.6 Drug Treatment for Protein extraction 
 
3 x105 MLEC cells were plated in a 6 well plate with 2ml MLEC medium (10%FBS). 
The following day the supernatant was removed and the cells were treated with 
either VEGF (30ng/ml), hIL-6 (30ng/ml), mIL-6 (30ng/ml) or VEGFRi (100nM) in 
serum free MLEC medium. At 24 hours the cells were lysed for protein extraction by 
using a commercial Extraction Buffer (1% Triton (Sigma -Aldrich) in which we 
added 1X protease inhibitor cocktail (Complete Mini Protease Inhibitor Cocktail, 
 65 
Roche, Burgess Hill, UK). Cells were then harvested using a cell scraper and the 
samples centrifuged at 4°C for 10 minutes. The cell pellet was discarded and the 
supernatant retained for protein quantification using the bicinchonic acid assay 
(BCA). Lysis was carried out at different time points depending on the protein 
analysed e.g. for pSTAT3 and pERK 5min, 30min, 2 hours, 6hours and 24hours were 
tested. For all the other ligands 6 hours and 24 hour time points were the standards 
time points analysed. 
3x105 IGROV-1 cells were plated in a 6 well plate with 2ml RPMI (10% FBS) 
medium. The following day the medium was replaced with serum free RPMI and the 
cells were treated with IgG/diluent (control), anti-IL-6 antibody (20µg/ml), VEGFRi 
(100nM) or anti-IL-6 + VEGFRi. After 24 hours of treatment the above-mentioned 
protein extraction method was carried out to lyse the cells. 
2.7 BCA assay  
 
The BCA assay was used to measure protein concentration. BCA combined with 
copper sulphate is a highly alkaline solution, with a pH around 11. Protein peptide 
bonds react with Cu2+ ions in the solution, reducing the ions to Cu1+, resulting in a 
colour change from green to purple as Cu1+ ions accumulate. This colour change is 
directly proportional to the amount of protein present, enabling quantification of 
protein concentration upon measurement of colour intensity.  
2.7.1 Procedure 
 
A BSA (Bovine Serum Albumine) stock solution at 50mg/ml was prepared and 
diluted to make concentrations of 5mg/ml and 2mg/ml. Working standards were then 
prepared depending on the estimated protein concentration as shown in the Table 5. 
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                            Table 5 Standard dilution used for the BCA assay 
 
  
 
Protein samples were diluted 1:10 or 1:5 with water, and 10µl of diluted sample were 
added to the 96 well plate in triplicates. 50 parts of bicinchoninic acid solution 
(Sigma, B9643-L) was combined with 1 part of copper (ii) solution (Sigma, C2284). 
200µl of this solution was added to each well. The plate was incubated for 30 minutes 
at 37°C and the optical density was then read using the Opsys MR plate reader 
(Dynex Technologies) at 595nm. 
2.8 Western blotting 
 
There are three main steps involved in Western Blotting and they include (i) 
separating the proteins according to their polypeptide chains using SDS gel 
electrophoresis, (ii) transferring them to a polyvinylidine fluoride (PVDF) membrane 
and (iii) detecting the protein of interest using specific antibodies. SDS is negatively 
charged and it solubilises the proteins. The negative charge on Sodium Dodecyl 
Sulphate (SDS) neutralises any positive charge present on the protein. This results in 
proteins having identical charge per unit mass, which helps their fractionation by 
size. The list of western blotting antibodies used and its dilutions are shown in Table 
6. 
 
BSA Solution Vol. BSA 
(µL) 
Vol. PBS (µL) Protein Concentration (µg/µL) 
0 100 0 
10 90 0.2 
20 80 0.4 
30 70 0.6 
40 60 0.8 
 
2mg/mL 
50 50 1.0 
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2.8.1 Procedure 
 
10% acrylamide gels were made using AccuGel 19:1 (National Diagnostics, 10-10-
07), 4x Protocol Resolving Buffer (National Diagnostics, 11-05-18), Protocol 
Stacking Buffer (National Diagnostics, 08-02-27), Ammonium persulfate (Sigma, 
104H0456) and TEMED (Sigma, 116H1117). Laemmli Buffer (62.5mM Tris-HCL, 
2% SDS, 25% Glycerol, 0.01% Bromophenol blue) was used as the loading buffer. It 
was added to each sample 1 in 6 according to the volume of protein solution then 
centrifuged briefly and incubated at 95ºC for 5 minutes. The samples were then 
loaded onto the gel next to a protein molecular weight standard (Biolabs Cambridge, 
size varying between 230-10kDa). Running buffer was prepared using 25mM Tris 
Base, 250mM glycine, 0.1% SDS in H2O (Invitrogen). The gel was run at 100V until 
the marker reached the bottom of the well. Using the Bio-Rad transfer system the 
resolved proteins were transferred onto the PVDF membrane (Perkin Elmer, 
Waltham, MA, US). In the transfer cassette, a sandwich was made between Scotch-
Brite pads, Chromatography paper (Whatman, Maidstone, Kent), gel and the 
membrane. The cassette was then placed in the transfer tank with an ice pack and 
filled with transfer buffer (27mM Tris, 192mM Glycine, 20% methanol). The transfer 
was run at 100 Amps for 90 minutes.  
In order to avoid non-specific binding, the membrane was blocked in blocking buffer 
(5% w/v skimmed milk powder (Marvel, Spanning, Lincolnshire) in TBST (50mM 
TrisHCL, 150mM NaCl, 0.1% TweenTM -20) for one hour at room temperature. After 
incubation, the blocking solution was removed and the primary antibody diluted in 
the blocking buffer according to the dilution shown in the table below. The 
membrane was then incubated overnight on a roller at 4ºC or incubated for 1 hour at 
room temperature. Following incubation with the primary antibody, the membrane 
was washed 3 times in TBST (5 minute each) and the secondary antibody 
horseradish peroxidase (HRP) conjugate was diluted 1:2000 and applied for 1 hour. 
This was followed by 3 washes (5 minute) in TBST at room temperature. The protein 
bands were visualised using ECL plus TM Western Blotting Detection Reagents 
(Amersham) and Hyperfilm ECL (Amersham). If required, membranes were 
 68 
stripped using 1X Re-blot Plus Strong (Millipore) for 5 minutes before incubation in 
blocking buffer. 
                            Table 6 Western blotting Antibodies and Dilution 
 
Primary Antibody Dilution Secondary Antibody Dilution 
pSTAT3 (Cell signalling, 
D3A7) 
1:1000 Rabbit 1:2000 
STAT3 (Cell signalling, 4904) 1:1000 Rabbit 1:2000 
pERK (Santa Cruz, sc-7383) 1:1000 Mouse 1:2000 
ERK (Cell signalling, 137F5) 1:1000 Rabbit 1:2000 
Jagged1 (Abcam, ab7771)  1:1000 Rabbit 1:2000 
DLL4 (Abcam, ab7280) 1:1000 Rabbit 1:2000 
Angiopoietin-2 (Abcam, 
ab8452) 
1:500 Rabbit 1:2000 
 HEY (Abcam, ab22614) 1:500 Rabbit 1:2000 
β-ACTIN (Sigma, A1978) 1:10000 Mouse 1:5000 
 
2.9 In vivo injection of IGROV-1 cell lines and anti-IL-6 
treatment  
 
8 weeks old Balb/c nude female mice were injected i.p with 1x107 IGROV-1-luc cells 
in 200µl of sterile, endotoxin free, PBS. After 24 hours, anti-IL-6 antibody (Med 
Immune) was prepared at a concentration of 20mg/kg in sterile, endotoxin free, PBS 
and mice were injected i.p with 200µl of this solution twice weekly for 4 weeks. 
Control mice were injected with 200µl of 20mg/kg IgG control antibody.  
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At 24 hours, 1 week, 2 weeks, 3 weeks and 4 weeks after tumour cell injection, mice 
were imaged in order to monitor tumour growth and spread by bioluminescent assay. 
For this purpose, mice were anaesthetised with isoflourane and injected with 100 µl 
luciferin i.p. (3 mg) 10 minutes before imaging (IVIS).  
2.10 Visualisation and staining of tumour blood vessels 
 
In order to visualise the architecture of blood vessels, 4 mice from each group were 
anaesthetised with isoflourane and injected with TRITC-conjugated Bandeiraea 
simplicifolia  (lectin; 100µl, 2mg/ml; Sigma L5264) via the tail vein, 3 min before being 
perfused with 4% paraformaldehyde. Following fixation overnight the resected 
primary tumours were cryoprotected in 12%, 15%, and 18% sucrose for 1 hour each. 
Tumours were subsequently snap frozen in ornithine carbamyl transferase compound 
(Sankura Finetek, Torrance, CA) and sectioned at 10µm intervals.  
The frozen sections from the lectin stained in vivo IGROV-1 xenograft study were 
then stained for pericyte markers by immunofluorescence. The slides were first 
washed in PBS X3 (5 min each) and a PAP pen was used to draw sections around 
the tumour areas. The slides were permeabilised with 0.1% Triton in PBS for 5 min 
at room temperature; washed again with PBS X2  (5 min each) and then blocked 
with blocking buffer (5% serum, 2.5% BSA in PBS) for 1 hour at room temperature. 
The primary antibodies were diluted in the blocking buffer i.e. 1 in 100 anti-α-SMA 
FITC (abcam, ab8211), 1 in 100 Mouse IgG2a (FITC) isotype control (ab81197), 1 
in 50 or anti-NG2 (Millipore, ab5320) were incubated overnight at 4ºC. The 
following day the sections were washed in PBS X3 (5 min each). Slides were then 
mounted with Prolong Gold DAPI containing medium (Invitrogen, P36931) and left 
to dry. Images were taken using confocal microscopy (Zeiss LSM S10 META). 
2.11 Immunohistochemistry 
 
Immunohistochemistry was performed on paraffin embedded sections of the 
remaining four mice from the two groups of the in vivo IGROV-1 tumours treated 
with the anti-IL-6 antibody (outlined in section 1.9). The antibodies and dilutions 
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used are summarised in Table 7. The streptavidin-peroxidase method used for 
immunostaining was performed on all tissue sections using the ABC kit (Vector 
Labs) with the following steps: 
 
1)  Tissue sections from the in vivo IGROV-1 xenografts were deparaffinised in 
xylene then rehydrated in graded ethanol as follows; 
xylene   2 x 5 min 
100% ethanol  2 x 2 min  
95% ethanol  2 x 2 min 
70% ethanol  2 x 2 min 
50% ethanol  1 x 2 min 
ddH20   2 x 2 min 
2) Antigen retrieval was carried out by immersing tissue sections in citrate buffer 
consisting of 2.5 ml Vector Antigen Unmasking solution (Vector laboratories, 
Peterborough, UK) in 250 ml ddH20 and microwaving at 700W in a chamber 
for 10 min; followed by incubation at RT for 15 min. 
 
3) Sections were washed in PBS X3 (5 min each). 
 
4) PAP pen (Vector Labs) was used to draw around the tumour areas. 
 
5) Sections were incubated in blocking buffer (rabbit or goat serum depending 
on species of antibody) for 45 min and drained. 
 
6) The primary antibodies diluted in blocking buffer was added to the slides and 
incubated overnight at 4°C.  
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7) The primary antibody was aspirated the next day and washed in 3X PBS (5 
min each). 
 
8) The slides were incubated with biotinylated secondary antibody diluted 1:200 
in blocking buffer at RT for 2 hours. 
 
9) Sections were washed in 3XPBS (5 min each). 
 
10) Avidin-Biotinylated enzyme Complex (ABC, Vectastain Standard Kit, Vector 
Laboratories, Peterborough, UK) was prepared and left on ice for at least 30 
min. 
 
11) Endogenous peroxide activity was blocked using 5ml of 30% H2O2 in 250 ml 
methanol at RT for 20 min. 
 
12) The slides were washed 3 times in PBS (5 min each). 
 
13) This was followed by incubation of the slides with Avidin-Biotinylated 
enzyme Complex in a covered humidified chamber at RT for 30 min. Sections 
were washed 3 times in PBS (5 min each). 
 
14) Peroxidase substrate was prepared by vortexing one diaminobenzidine 
(DAB) tablet with one Tris/peroxide tablet in 15ml dH2O (Sigma Aldrich, 
Gillingham, UK, D4418). The DAB solution was applied through a 0.45µm 
filter and sections were incubated for 3-20 min. 
 
 
15) The sections were then briefly washed in water and counterstained in 
haematoxylin for 1 min, then immersed in differentiating solution (750µl 
ammonium hydroxide in 250 ml dH2O). 
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16) Slides were dehydrated as follows; 
100% isobutanol 20 dips 
100% isobutanol  2 x 2 min 
xylene   2 x 2 min 
17)  Sections were cleared and mounted whilst moist with DPX (Fisher, 
Loughborough, UK); coverslips were placed and slides left to air dry. 
 
               Table 7 Summary of Primary Antibodies for IHC analysis 
 
Primary antibody Dilution 
Secondary antibody 
species 
DLL4 
(R&D Systems, 
af1389) 
1:100 
 
Goat 
 
Jagged-1 
(R&D Systems, 
af1277) 
1:100 
 
Rabbit 
 
Angiopoietin 2 
(Abcam, ab8452) 
1:50 
 
Rabbit 
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3 Actions of IL-6 in a model of angiogenesis  
 
3.1 Aortic ring assay 
 
Many experimental models have been developed to study the mechanism of 
angiogenesis and to test the efficacy of the anti-angiogenic agents [175]. These 
experimental models include in vitro cell based assays such as the endothelial tube 
formation or chemo-attractant induced endothelial cell migration assays. Then there 
are in vivo models of tumour angiogenesis or subcutaneously implanted sponges or 
matrigel plug assays [176].  
There are several advantages and disadvantages to these methods. The in vivo 
angiogenesis techniques involve various cell types with a complex balance of pro and 
anti-inflammatory factors that work together to regulate blood vessel formation. This 
helps to fully understand the process of neovascularisation. The in vivo tumour models 
also have disadvantages e.g. they are relatively expensive and they also involve 
inflammatory and other stromal components which make it difficult to understand 
the direct effect of the malignant or stromal cells on angiogenesis. The implantation of 
the sponge or matrigel plugs may also stimulate inflammation and thereby further 
affect the process of angiogenesis [176].  
These problems can be avoided in the in vitro endothelial cell assays, which are 
comparatively less expensive and growth factor stimulation can be studied directly 
without any interference from other cell types. However this system lacks sprouting 
of blood vessels and there is also absence of pericytes, which are important in the 
stabilisation of the vessels. These problems can be avoided by using the aortic ring 
model which is an ex vivo assay that bridges the gap between existing in vivo and in 
vitro assays [177]. 
Aortic ring cultures are composed of mixed populations of endothelial cells, pericytes, 
fibroblasts, macrophages and dendritic cells. The first cells to migrate out of the 
aortic rings after 1-2 days are fibroblasts and macrophages. Endothelial sprouts 
appear after 2-3 days of culture. The neovessel tips are made of highly migratory 
cells, which probe the surrounding matrix with filopodia-like processes. Staining for 
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cell proliferation markers such as Ki-67 show that the endothelial tip cells migrate 
without diverting whilst trailing endothelial cells actively proliferate. Over time 
neovessels become surrounded by pericytes, which migrate and proliferate along the 
endothelium. After sprouting, branching and forming networks for approximately 1-2 
weeks, vessels stop growing and begin to regress [177]. 
I decided to use the aortic assay to test the angiogenic potential of IL-6 and to ask if 
IL-6 alone could stimulate microvessel outgrowths.  
3.2 Setting up the Aortic ring Assay 
 
I wanted to first establish this model of angiogenesis in my lab by optimising various 
conditions. The first series of aortic ring experiments were set up to establish sprout 
formation in my positive control group using VEGF, which has been long studied for 
its angiogenic effects on endothelial cells [176]. 
 
Figure 3.1Phase-contrast images of aortic rings embedded in type I collagen 
showing microvessel outgrowth.  
Aortas removed following cervical dislocation of 8-12 week old mice were treated with optimem 
medium containing 1% FCS (A) or recombinant VEGF (R&D) at 30ng/ml (B) for 2 weeks. The 
medium was changed every 3 days and the rings were imaged using phase contrast microscopy. 
 
Figure 3.1A shows the growth of fibroblasts from an aortic ring grown in medium 
containing 1% FCS. This ring did not however produce any microvessel growth and 
was used as a negative control. In case of the positive control there were extensive 
sprouting vessels visible in the aorta treated with recombinant VEGF (30ng/ml) 
A Medium + 1% FCS     VEGF (30ng/ml) B 
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(Figure 3.1B). I was able to overcome the difficulty of optimising VEGF 
concentration, since other departments in my Institute have already studied the 
effects of VEGF on the aortic ring assay. Therefore, I only attempted a small 
optimisation experiment testing 20, 30 and 40ng/ml, which suggested there was not 
much difference between the 30 and 40ng/ml of VEGF on sprouting. VEGF 
optimisation studies in other labs have also shown that higher concentrations of 
VEGF inhibited vessel growth. I carried out a small experiment to test the effects of 
high concentration of VEGF on blood vessel formation in the aortic ring assay.  
 
Figure 3.2 Phase-contrast images of aortic rings embedded in type I collagen for a 
period of two weeks.  
Aortas removed following cervical dislocation of 8-12 week old mice were treated with optimem 
medium containing 1% FCS (A) or recombinant VEGF (R&D) at 150ng/ml (B) for 2 weeks. The 
medium was changed every 3 days and the rings were imaged using phase contrast microscopy. 
 
Figure 3.2B shows that at concentrations of 150ng/ml and above VEGF can have an 
inhibitory effect on sprout formation and this agreed with the findings of other labs in 
our centre. Some studies have indicated that the extension and maintenance of the tip 
cell is dependent on VEGF signalling via the receptor VEGFR2 [178]. It was 
reported that high concentrations of VEGF can trigger high levels of DLL4 which in 
turn can inhibit VEGFR2 and thereby dampen the responsiveness of VEGF to its 
receptor [179]. This could be a possible explanation for the inhibitory effect observed 
with high levels of VEGF on sprout formation in the aortic ring assay. 
A B     VEGF (150ng/ml) Medium + 1% FCS 
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Figure 3.3 Mean number of sprouts in aortic rings treated with Medium and 
VEGF. 
 Aortas removed following cervical dislocation of 8-12 week old mice were treated with optimem 
medium containing 1% FCS or 30ng/ml VEGF (R&D) for 2 weeks. The medium was changed every 3 
days. The rings were imaged using phase contrast microscopy and microvessel outgrowth was counted 
and quantified. Combines results from 2 independent experiments. * Represents statistical significance 
(p value < 0.005). 
 
One of the angiogenic parameters that can be measured using the aortic ring assay is 
quantification of the number of microvessel sprouts to determine the potency of the 
angiogenic agent. This was usually carried out towards the end of the experiment by 
counting the number of branching vessels under the microscope then calculating the 
mean per condition. There were significantly more sprouts in the VEGF treated 
aortic rings compared to the medium treated aortic rings as shown in Figure 3.3. This 
experiment was repeated in order to optimise various experimental conditions and to 
obtain consistent results.  
 
 
 
 
  * 
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3.3 To study the effects of human IL-6 in the mouse aortic 
ring assay  
Next, I wanted to investigate the effect of IL-6 on angiogenesis using the aortic ring 
assay.  A human anti-IL-6 (hIL-6) antibody was effective in reducing the tumour 
vasculature in IGROV-1 xenograft, suggesting that the hIL-6 produced by the 
malignant cells had a paracrine effect on mouse endothelial cells [35]. Hence, I 
wanted to ask if a recombinant hIL-6 could stimulate microvessel formation in the 
mouse aortic ring assay. Initially, I set up an aortic ring assay with 30ng/ml of hIL-6, 
the same concentration used for VEGF and the study showed fibroblast production 
without any microvessel growth. I therefore, carried out a dose response experiment 
with increased concentrations of hIL-6. 
 
 
Figure 3.4 Phase-contrast images of aortic rings embedded in type I collagen 
showing microvessel outgrowth.  
Aortas removed following cervical dislocation of 8-12 week old mice were treated with optimem 
medium containing 1% FCS (A), hIL-6 (R&D) at 50ng/ml (B) hIL-6 (R&D) at 100ng/ml (C) hIL-6 
(R&D) at 150ng/ml or (D) hIL-6 (R&D) at 200ng/ml, for 2 weeks. The medium was changed every 3 
days and the rings were imaged using phase contrast microscopy. 
    hIL-6 100ng/ml       hIL-6 50ng/ml A B 
    hIL-6 150ng/ml C     hIL-6 200ng/ml D 
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Figure 3.4 shows an aortic ring experiment with recombinant hIL-6 at varying 
concentrations i.e. 50ng/ml (A), 100ng/ml (B), 150ng/ml (C) and 200ng/ml (D). 
Sprout formation is visible in Figure 4.3 (A), (B) and (C), indicating 50-150ng/ml of 
hIL-6 is pro-angiogenic and can stimulate microvessel growth. Concentrations higher 
than 150ng/ml as shown in Figure 3.4(D) have attenuating effect on vessel growth, 
indicating similar to VEGF, too high concentration of hIL-6 can be toxic to vessel 
formation.  
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Mean number of sprouts in aortic rings treated with Medium, VEGF 
and hIL-6. 
Aortas removed following cervical dislocation of 8-12 week old mice were treated with optimem 
medium containing 1% FCS with 30ng/ml VEGF (R&D) or 50ng/ml hIL-6 (R&D) for 2 weeks. The 
medium was changed every 3 days. The rings were imaged using phase contrast microscopy and 
microvessel outgrowth was counted and quantified. Combined results from 3 independent 
experiments. * Represents statistical significance. Medium vs VEGF (p value < 0.002), medium vs 
hIL-6 (p value < 0.002). 
 
Figure 3.5 shows that the mean number of sprouts in aortic rings treated with 
medium, VEGF 30ng/ml and hIL-6 50ng/ml. There was a significant difference 
between the number of sprouts induced by medium compared to VEGF and hIL-6, 
however there was no significant difference in vessel sprouting observed between 
VEGF and hIL-6 treated aortic rings at these doses. The molecular weight of VEGF 
and IL-6 are very similar hence the molar concentrations were 1.4µM for 30ng/ml 
VEGF and 2.0µM for 50ng/ml of hIL-6. Higher concentrations of hIL-6 might be 
*   * 
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required compared to VEGF because of the specificity of the mouse VEGF to mouse 
aortic ring compared to hIL-6 on mouse aortic ring. There were some anomalous 
rings which either produced too high or too low number of sprouts. Hence, the 
highest and lowest outliers from both groups were eliminated from the mean. 
Collectively, results from Figure 3.4 and 3.5 indicate that hIL-6 itself can induce 
microvessel growth and is as potent as VEGF in the aortic ring assay. 
 
 
 
 
 
 
 
 
 
Figure 3.6 Mean length of sprouts in aortic rings treated with VEGF or hIL-6. 
 Aortas removed from 8-12 week old mice were treated with optimem medium containing 1% FCS 
with 30ng/ml VEGF (R&D) or 50ng/ml hIL-6 (R&D) for 2 weeks. The medium was changed every 3 
days. The rings were imaged using phase contrast microscopy and the length of sprouts was measured 
using ImageJ analysis. Results from 3 independent experiments, average of three rings each per 
experiment.  
 
Another angiogenic parameter that can be measured with the aortic ring assay is the 
length of the sprouting vessels. This also gives an indication of the proliferation 
capacity of the stalk cells in the presence of the angiogenic stimulator or inhibitor. 
This is usually carried out using the ImageJ software by drawing radial lines from 
the base of the aortic ring to the lengths of the sprouting microvessel and saving these 
data to calculate average values per treatment. Figure 3.6 shows that there was no 
significant difference in the lengths of sprouts between the VEGF and hIL-6 treated 
groups. 
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3.4 To study the effects of mouse IL-6 in the mouse aortic 
ring assay 
 
Once the effects of hIL-6 on mouse aortic ring assay were established, it was 
important to confirm this effect using recombinant mouse IL-6 (mIL-6). This would 
give further validation of the binding of the recombinant protein to its receptor and 
also verify the effects observed with hIL-6. In order to investigate the effects of mIL-
6, first an optimisation experiment was carried out with differing concentrations of 
mIL-6. 
 
 
Figure 3.7 Phase-contrast images of aortic rings embedded in type I collagen 
showing microvessel outgrowth.  
Aortas removed following cervical dislocation of 8-12 week old mice were treated with optimem 
medium containing 1% FCS (A), mIL-6 (R&D) at 30ng/ml (B) mIL-6 (R&D) at 50ng/ml (C) mIL-6 
(R&D) at 100ng/ml and (D) and mIL-6 (R&D) at 200ng/ml, for 2 weeks. The medium was changed 
every 3 days and the rings were imaged using phase contrast microscopy. 
A B 
C D 
  mIL-6 30ng/ml   mIL-6 50ng/ml 
  mIL-6 100ng/ml   mIL-6 150ng/ml 
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Figure 3.8 Mean number of sprouts in aortic rings treated with Medium, VEGF 
or   mIL-6.  
Aortas removed following cervical dislocation of 8-12 week old mice were treated with optimem 
medium containing 1% FCS, 30ng/ml VEGF (R&D) or 30ng/ml mIL-6 (R&D) for 2 weeks. The 
medium was changed every 3 days. The rings were imaged using phase contrast microscopy and 
microvessel outgrowth was counted and quantified. Results from 2 independent experiments are 
shown above. Medium vs VEGF ( p value < 0.06), medium vs mIL-6 ( p value < 0.06) 
 
Figure 3.7 shows the phase contrast images for the dose response experiment carried 
out with mIL-6 at 30, 50, 100 and 200ng/ml. The results indicated that concentrations 
as low as 30ng/ml of mIL-6 can induce microvessel sprouting. Similar to hIL-6, high 
concentrations of mIL-6 i.e. 200ng/ml had an inhibitory effect on vessel sprouting. 
This experiment verified the previous angiogenic effects observed with hIL-6 on 
mouse aortic rings. 
 
After the completion of the initial mIL-6 dose response experiment, aortic ring 
experiments were set up to quantify the difference in 30ng/ml VEGF and 30ng/ml 
mIL-6 induced sprouting.  Figure 3.8 shows the mean number of sprouts between 
VEGF and mIL-6 treated aortic rings. The quantification of number of sprouts 
between medium and VEGF and mIL-6 just failed to reach significance. This could 
have been because the sprouting witnessed in the above mIL-6 experiment (Figure 
3.8) was relatively low compared to the initial dose response experiment (Figure 3.7). 
It was clear there were some inconsistencies in the mouse aortic ring experiments. 
 82 
This could have happened because the mice used sometimes were older than 12 
weeks resulting in more accumulation of fat around the aortas, which makes it 
difficult to remove the fat and ultimately leads to tissue damage. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 Mean length of sprouts in aortic rings treated with VEGF or mIL-6.  
Aortas removed following cervical dislocation of 8-12 week old mice were treated with optimem 
medium containing 1% FCS with either 30ng/ml VEGF (R&D) or 30ng/ml mIL-6 (R&D) over a 
course of 2 weeks. The medium was changed every 3 days. The rings were imaged using phase 
contrast microscopy and the length of sprouts was measured using ImageJ analysis. Results from 2 
independent experiments, n= 5 for VEGF and 7 for mIL-6. 
 
Figure 3.9 shows the quantification of length of sprouts between VEGF and mIL-6 
treated aortic rings. The results were quantified as mentioned earlier by using the 
ImageJ software by drawing radial lines from the base of the aortic ring to the 
lengths of the sprouting microvessel and saving these data to calculate average values 
per treatment. The above results were similar to the results obtained with the hIL-6 
and showed no significant difference in the lengths of sprouts between the VEGF and 
mIL-6 treated groups.  
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3.5 To study the effects of rat IL-6 in the rat aortic ring 
assay 
 
Due to the difficulty in obtaining enough rings to gather consistent data from the 
mouse aortic ring experiments, I decided to experiment with rat aortic rings, which 
had been tested and shown to be more sensitive to VEGF by other labs in my 
Institute. Rat aortas are considerably bigger in size than mouse aortas, hence, around 
25-30 rings can be cut from each rat aorta compared to 15-20 rings from the mouse 
aortas. This increases the success rates of each experiment by allowing the use of 
more rings per condition and also helps in the handling of the aortas since they are 
not so easily damaged as mouse aortas. Also, unlike the mouse aortic ring 
experiments, which usually take two weeks to obtain results, the rat assay only 
requires about a week in culture with just two medium changes. Rat aortic rings had 
already been tested by one of our collaborators who had also established the optimal 
dose of VEGF (10ng/ml) to be used in the rat aortic ring assay. Therefore, for the 
dose response experiment of rIL-6, I used 10ng/ml as the initial starting 
concentration. 
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Figure 3.10 Phase-contrast images of aortic rings embedded in type I collagen 
showing microvessel outgrowth. 
Aortas removed following cervical dislocation of 180-200g wistar male rats were treated with optimem 
medium containing 1% FCS (A), rIL-6 (R&D) at 10ng/ml (B) rIL-6 (R&D) at 30ng/ml (C) rIL-6 
(R&D) at 50ng/ml and (D) rIL-6 (R&D) at 100ng/ml, for one week. The medium was changed every 
3 days and the rings were imaged using phase contrast microscopy. 
 
As shown in Figure 3.9, concentrations starting from 10-100ng/ml of rIL-6 were 
capable of inducing sprouting in the rat aortic ring assay. The results were similar to 
hIL-6 and mIL-6 dose response experiments, high concentrations of rIL-6 resulted in 
less microvessel outgrowths. Since the rat aortic rings are considerably bigger in size 
than mouse aortic rings it was not possible to take phase contrast image of the entire 
rings.  
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Figure 3.11 Mean number of sprouts in rat aortic rings treated with medium, 
VEGF or rIL-6.  
Aortas removed following cervical dislocation of 180-200g rats were treated with optimem medium 
containing 1% FCS with either 10ng/ml VEGF (R&D) or 10, 30, 50 or 100ng/ml rIL-6 (R&D) for one 
week. The medium was changed every 3 days. The rings were imaged using phase contrast microscopy 
and microvessel outgrowth was counted and quantified.*Represents statistical significance. Medium vs 
VEGF (p value < 0.01), medium vs rIL-6 10ng/ml (p value < 0.03) 
 
Figure 3.10 shows the results of the rIL-6 dose response experiment with 10, 30, 50 
and 100ng of rIL-6. Among the varying concentrations of rIL-6 used, concentrations 
from 10-100ng/ml of rIL-6 led to formation of microvessel growth. There were 8 
aortas used per condition and out of those 10ng/ml of VEGF and rIL-6 led to blood 
vessel formation in 90% of the aortas. Concentrations from 30-100ng/ml of rIL-6 
resulted in 50% sprouting, however the mean number of sprouts per ring was 
considerably lower in these groups compared to 10ng/ml of rIL-6. This experiment 
showed 10ng/ml of rIL-6 to be the ideal concentration to use in the rat aortic ring 
assay. 
After deciding on the concentration of rIL-6, I went on to carry out a repeat for the 
rat aortic ring experiment with 10ng/ml of VEGF and rIL-6. 
 
 
A 
 * 
 * 
* 
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Figure 3.12 Mean number of sprouts in aortic rings treated with Medium, VEGF 
or rIL-6.  
Aortas removed following cervical dislocation of a 180-200g rats were treated with optimem medium 
containing 1% FCS with 10ng/ml VEGF (R&D) or 10ng/ml rIL-6 (R&D) over a course of 2 weeks. 
The medium was changed every 3 days. The rings were imaged using phase contrast microscopy and 
microvessel outgrowth was counted and quantified. * Represents statistical significance. Medium vs 
VEGF ( p value < 0.01), medium vs rIL-6 ( p value < 0.02). 
The second rat aortic ring repeat experiment (Figure 3.11) agreed with the initial 
dose response experiment and showed no significant difference in the number of 
sprouts between VEGF and rIL-6 treated aortic rings. There was a significant 
difference in the number of sprouts in media vs 10ng/ml VEGF and media vs 10ng/ml 
rIL-6 treated aortic rings.  
Collectively these aortic ring experiments show that human, mouse and rat IL-6 can 
induce sprouting in mouse and rat aortic ring assays and that there is no significant 
difference in the number of sprouts between VEGF and IL-6 treated rings. 
Concentrations of 50ng/ml of hIL-6 and 30ng/ml of mIL-6 in mouse aortic ring and 
10ng/ml of rIL-6 in rat aortic ring were effective in inducing microvessel growth. 
However, higher concentrations such as 150ng/ml of hIL-6 and 200ng/ml of mIL-6 
were shown to have inhibitory effect on sprout formation in the mouse aortic ring 
assay. There was also no significant difference in the length of sprouts between hIL-6 
and mIL-6 treated rings with VEGF treated rings in the mouse aortic ring assay. This 
chapter shows IL-6 is as effective as VEGF in inducing angiogenesis in the aortic 
ring assay. In the next set of experiments I wanted to study the direct effects of IL-6 
on endothelial cells. 
*   * 
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4 The interaction of IL-6 with mouse 
endothelial cells  
 
Once it was established that IL-6 could drive angiogenesis in the aortic ring assay, it 
was important to study the interaction of IL-6 with endothelial cells. In order to 
investigate this I used a primary mouse lung endothelial cell line (MLEC), which was 
kindly given to me by members of Prof Kairbaan Hodivala Dilke’s group. The 
generation of the cell line is briefly described in the methods section 2.2. 
I wanted to use this endothelial cell line as a tool to understand the effects and 
mechanisms of IL-6 on inducing different stages of angiogenesis. The experiments I 
planned to do with MLEC were:  
• Investigate if IL-6 can drive MLEC proliferation and migration.  
• Study the existence and functionality of the IL-6Rα in MLEC  
• Study downstream target of IL-6 i.e. pSTAT3 after treatment with VEGF, to 
determine if VEGF can induce IL-6 signalling in endothelial cells. 
• Study downstream target of VEGF i.e. pERK after stimulation with IL-6, to 
determine if IL-6 can induce VEGF signalling in endothelial cells.  
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4.1 The effects of IL-6 on MLEC proliferation 
 
First, I wanted to investigate if human and mouse IL-6 can drive mouse endothelial 
cell proliferation and if there is a difference between VEGF and IL-6 induced MLEC 
proliferation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1Graph showing the effects of VEGF, hIL-6 or mIL-6 on cell 
proliferation in MLEC. 
70,000 MLEC were plated and treated with either PBS (Control), VEGF (50 or 100ng/ml), hIL-6 (50 
or 100ng/ml) or mIL-6 (50 or 100ng/ml) for 72 hours. The cells were then trypsinised and counted 
using a cell counter and the mean of the triplicates were calculated. *Represents statistical significance. 
Control vs VEGF 50 (p value < 0.0008), control vs VEGF 100 (p value < 0.0001), control vs hIL-6 
100 (p value < 0.004), control vs mIL-6 50 (p value < 0.02), control vs mIL-6 100 (p value < 0.001). 
Results typical of 3 independent experiments. 
 
Figure 4.1 shows the effect of VEGF, hIL-6 and mIL-6 on MLEC proliferation. The 
concentration of VEGF was decided based on observation from previous studies, 
where doses ranging from 50-100ng were used in in vitro cell based assays with 
VEGF [180]. The molar doses used for VEGF was very similar to that used for hIL-
6 and mIL-6 and this helped to compare the effects on endothelial cell proliferation 
over a period of 72 hours. As shown in Figure 4.1, 50 and 100ng/ml of VEGF had a 
significant effect on endothelial cell proliferation. In the case of hIL-6 there was no 
significant increase in proliferation at 50ng/ml, however there was a significant 
 * 
  * 
    * 
   * 
    * 
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increase in the MLEC proliferation with 100ng/ml of hIL-6 compared to control. In 
the case of mIL-6, there was a significant increase in MLEC proliferation at 50 and 
100ng/ml. 
 
4.2 The effects of IL-6 on MLEC migration in the scratch 
assay 
Since endothelial cell migration plays a major role in tumour angiogenesis, I then 
wanted to study the effects of IL-6 on endothelial cell migration using the MLEC 
line. In order to do this, I decided to set up a scratch assay using a time lapse 
microscopy. The scratch assay is commonly used to study in vitro cell migration. This 
assay is carried out by creating a scratch on a cell monolayer, which causes the cells 
at the edge to move inwards to close the scratch. Using a time lapse microscopy, 
‘wound’ closure can be measured by comparing images captured at the onset with the 
ones taken at endpoint or with the ones taken at intervals. I used VEGF as a positive 
control [181]. 
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Figure 4.2 Graph showing the effects of control and mIL-6 on cell migration in 
MLEC. 
70,000 MLEC were plated on a 12 well plate and once the cells were confluent, scratch was made 
using a p20 tip in the centre of the well to make the ‘wound’. The medium was then changed and the 
cells were treated with either PBS (control) or mIL-6 (100ng/ml) for 16hours. Images were taken of 
the wound closure every hour using a time-lapse microscopy.           Indicates the ‘wound’ 
 
 
Figure 4.2 shows examples of phase contrast images of scratch assay taken using a 
time-lapse microscope at 0 and 16 hours. A dose response experiment with 
concentrations of 25-100ng/ml of VEGF and IL-6 was conducted. Since there is 
always some variation in the size of the scratch made using a p20 tip, it was important 
to take this into consideration when comparing the migration between different 
conditions. A formula is generally used to calculate the difference in the area of the 
‘wound’ at zero hours and at the end of the assay (see methods for more detail). 
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Figure 4.3 Graph showing the effects of VEGF, hIL-6 or mIL-6 on cell migration 
of MLEC.  
70,000 MLEC were plated on a 12 well plate and once the cells were confluent, scratch was made 
using a p20 tip in the centre of the well. The medium was then changed and the cells were treated with 
PBS (Control), VEGF (100ng/ml), hIL-6 (100ng/ml) or mIL-6 (100ng/ml) for 16hours. Images were 
taken of the wound closure every hour using a time-lapse microscopy. * Represents statistical 
significance.  Results typical of 3 independent experiments. Control vs VEGF 100ng (p value < 0.02), 
control vs hIL-6 100ng (p value < 0.05), control vs VEGF (p value < 0.03) control vs mIL-6 (p value < 
0.04). 
 
Figure 4.3 shows the results of the scratch assay after treatment of MLEC with 
VEGF, hIL-6 or mIL6. There was a significant difference in the percentage cell 
migration in the VEGF or hIL-6 treated wells as compared to the control group in 
Figure 4.3. There was also a significant difference in the percentage cell migration of 
MLEC in the VEGF and mIL-6 treated groups. 100ng/ml of human and mouse IL-6 
 *  * 
 * 
 * 
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is almost as potent as VEGF in inducing MLEC cell migration in scratch assays. 
Concentrations below 100ng/ml of VEGF, hIL-6 and mIL-6 did not show a 
significant effect on MLEC migration. 
4.3 IL-6Rα  (gp80) on endothelial cells 
There has been conflicting evidence on the existence of IL-6Rα on endothelial cells. A 
study conducted by Nillson et al, showed that tumor associated microvascular endothelial 
cells residing in the peritoneum expressed IL-6Rα [47]. The endothelial cell IL-6Rα was 
functional and when stimulated with IL-6 led to activation of STAT3. However, a study 
later conducted by Lo et al, investigating the effects of IL-6 trans signalling in malignant 
ovarian cancer ascities suggested that endothelial cells lack IL-6Rα expression [161]. 
Therefore, it was important to investigate and confirm the existence of IL-6Rα on 
MLEC and I decided to test this using immunofluorescence and western blotting 
analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Confocal images of the IL-6Rα staining in MLEC.  
2x105 MLEC were plated on cover slips in a 12 well plate. The cover slips were stained with (A) 
Rabbit IgG (R&D) or (B) anti-IL-6Rα antibody (Santa cruz) overnight at 4°C and secondary anti-
rabbit Alexa 488 for 2 hours at room temperature. The coverslips were then mounted on slides 
with Prolong Gold DAPI (blue) containing medium.  The image displays DAPI nuclear staining 
(blue) and IL-6Rα membrane staining (green) Scale bar = 20 microns.  
B 
A 
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Figure 4.4 shows the immunofluorescent confocal microscopy staining of IL6Rα on 
MLEC. The negative control (Figure 4.4A) is of MLEC treated with the secondary 
antibody mounted with DAPI (blue), showed staining of nucleus without any 
background. Figure 4.4 (B) shows a positive IL-6Rα (green) membrane staining in 
MLEC. This result correlates with the earlier published findings of Nilsson et al [47].  
 
4.4 To determine if the IL-6Rα  present in MLEC is 
functional 
 
I next wanted to show that the IL-6Rα on MLEC is functional and that it can signal 
via downstream IL-6 targets. In order to determine this, I decided to look at pSTAT3 
levels, which is the direct downstream read out of IL-6 signalling. I investigated the 
pSTAT3 levels using immunofluorescence and western blotting analysis. Since I 
observed sprouting after treatment with human and mouse IL-6, I decided to look at 
pSTAT3 after treatment of MLEC with either human and mouse IL-6.  
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Figure 4.5 Confocal images of the pSTAT3 staining in MLEC. 
 2x105 MLEC cells were plated on cover slips in a 12 well plate and treated with either PBS (Control), 
30ng/ml hIL-6 (B) or mIL-6 (C). Following 24 hours (A) was stained with rabbit IgG (B) and (C) 
were stained for pSTAT3 (green) overnight at 4°C. The next day the cells were stained with 
secondary anti-rabbit Alexa 488 for 2 hours at room temperature. The coverslips were then 
mounted on slides with Prolong Gold DAPI (blue) containing medium. Scale bar = 20 microns. 
A 
B 
C 
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Figure 4.5 shows the confocal staining of pSTAT3 (green) on MLEC. The negative 
controls used were either untreated MLEC stained for the secondary antibody 
(Alexa 488) or human/mouse IL-6 treated MLEC stained for secondary antibody. 
Figure 4.5 (A) shows DAPI (blue) staining in the negative control without 
background. Figure 4.5 (B) and (C) show positive pSTAT3 staining in the nucleus 
for human and mouse IL-6 treated MLEC. This showed that IL-6Rα in MLEC is 
functional and it can bind recombinant human and mouse IL-6 to induce 
downstream pSTAT3 signalling. I also wanted to verify the functionality of the 
receptor using western blotting analysis. 
 
 
 
 
 
 
 
Figure 4.6 Western blot showing the expression of pSTAT3 in MLEC after 
treatment with hIL-6 or mIL-6.  
2X105 cells of MLEC were plated and treated with either PBS (Control), hIL-6 (30ng/ml) or mIL-6 
(30ng/ml) for 24 hours. The cells were then lysed and 20ng of protein was loaded for western blot 
analysis. pSTAT3 and STAT3 levels were analysed and loading control was measured using β-actin. 
 
Figure 4.6 shows the levels of pSTAT3 in MLEC after treatment with human or 
mIL-6. There was an induction of pSTAT3 after treatment with both human and 
mIL-6 treated groups as compared to the control without any changes in the total 
protein levels. Total protein levels were measured to determine the changes in 
phosphorylated protein fraction with treatment relative to the total fraction. The 
loading control measured with β-actin was consistent between the different groups. 
This was an additional confirmation for the existence and function of the IL-6Rα in 
MLEC. 
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4.5 IL-6Rα  (gp80) in the aortic ring assay 
 
In order to confirm the angiogenic effects seen in the aortic ring assay after treatment 
with IL-6, it was then important to study the expression of IL-6Rα in the aortic ring 
assay.  
 
 
 
Figure 4.7 Confocal images of IL-6Rα  on vessels in mouse aortic ring treated 
with VEGF (30ng/ml) or mIL-6 (30ng/ml).  
Aortic ring assay treated with VEGF or mIL-6 were stained for endothelial vessels using BS1 lectin 
(green), IL-6Rα (red) and DAPI (blue). Scale bar = 20 microns. 
      VEGF 30ng/ml 
      mIL-6 30ng/ml 
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Figure 4.7 shows the staining for IL-6Rα in the aortic ring vessels after treatment 
with VEGF or mIL-6. As witnessed with MLEC, in the aortic ring vessels (green), 
there was positive staining for the IL-6Rα (red). This confirms that the IL-6Rα is not 
only present in the mouse endothelial cell line but also on endothelial cells in the 
aortic ring assay. I then tried to stain the aortic ring vessels for pSTAT3, however I 
was unable to do this successfully. 
 
4.6 Downstream signalling pathways after IL-6 and VEGF 
stimulation of MLEC cells 
    After establishing the existence and functionality of IL-6Rα in endothelial cells, I 
wanted to explore the differences in IL-6 and VEGF induced signalling in MLEC and 
investigate if the two pathways are dependent on each other for their angiogenic 
effects. I first asked if VEGF can induce downstream IL-6 signalling i.e. pSTAT3 in 
MLEC. In order to do this, I decided to carry out a time point experiment to determine 
the optimal time for IL-6 induced pSTAT3 induction and to study if VEGF can induce 
pSTAT3 at any of those time points. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Western blot showing the expression of pSTAT3 in MLEC after 
treatment with mIL-6 at 2h, 6h, 24h and 48h.  
2X105 cells of MLEC were plated and treated with either PBS (Control), mIL-6 (30ng/ml) or VEGF 
(30ng/ml) for 2h, 6h, 24h or 48hours. The cells were then lysed and 20ng of protein was loaded for 
western blot analysis. pSTAT3 and STAT3 levels were analysed and loading control was measured 
using β-actin. 
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Figure 4.8 shows the induction of pSTAT3 over a course of 2 hours to 48 hours. 
There was a gradual increase of pSTAT3 from 2 hours to 24hours with the highest 
induction at 24 hours after treatment with mIL-6. At 48 hours the levels of pSTAT3 
levels started to decrease showing a cycling induction of pSTAT3 with mIL-6 
treatment. Therefore, the optimum time point for investigating stimulation of 
pSTAT3 by mIL-6 seems to be the 24 hour time point. 
The other observation that can be made from Figure 4.8 is that VEGF did not seem 
to induce pSTAT3 in MLEC at any of those time points. Hence, according to this 
finding VEGF signalling is not dependent on IL-6 signalling in MLEC and suggests 
that VEGF does not induce IL-6. 
 
4.7 Does IL-6 induce VEGF in MLEC? 
Once I established that the IL-6Rα is functional on MLEC, I wanted to investigate if 
IL-6 can induce VEGF signalling. In order to study this, I decided to look at the 
downstream target of VEGF, i.e. pERK, 24 hours after treatment with mIL-6 or 
VEGF in MLEC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Western blot showing the expression of pERK in MLEC after 
treatment with mIL-6 or VEGF.  
2X105 cells of MLEC were plated and treated with either PBS (Control), mIL-6 (30ng/ml) or VEGF 
(30ng/ml) for 2 hours, 6 hours and 24 hours. The cells were then lysed and 20ng of protein was loaded 
for western blot analysis. pERK and ERK levels were analysed and loading control was measured 
using β-actin. 
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Figure 4.9 shows that, as expected, there is pERK induction after treatment of 
MLEC with VEGF at 2 hours, 6 hours and 24 hours. However, there did not seem to 
be an induction in pERK levels after treatment with mIL-6. I did not see any 
difference in the level of pERK in the mIL-6 and VEGF treated MLEC in the 48hour 
time point. The levels of the total protein (ERK) and the loading control (β-actin) 
remain consistent between the different groups. This shows that IL-6 might not 
signal via VEGF i.e. pERK in MLEC. This gives an indication that IL-6 and VEGF 
might have different mechanism of action on endothelial cells. The induction of 
pSTAT3 and pERK with IL-6 and VEGF were also repeated at early time points (30 
min and 2 hours) and similar results were observed (data not shown). 
 
In conclusion, I was able to confirm that IL-6 was active on endothelial cells using in 
vitro proliferation and migration assays. I then confirmed the existence and 
functionality of the IL-6Rα in MLEC by looking at its downstream target pSTAT3. I 
was also able to show that hIL-6 can also induce pSTAT3 in MLEC, which 
correlates with the sprouting observed with hIL-6 in the mouse aortic ring assay. In 
order to obtain an insight into the mechanism of action of IL-6 on endothelial cells, I 
also looked at the interaction of IL-6 with VEGF signalling. According to the data 
obtained from the western blot analysis of pSTAT3 and pERK after treatment with 
IL-6 and VEGF, it seems as if the two pathways are independent of each other, at 
least in MLEC. The data suggest that IL-6 might have a different mechanism of 
action in inducing angiogenesis as compared to VEGF. This will require further 
investigation in other assays such as the aortic ring assay. 
 
Although technically challenging, I would aim to extract protein from the aortic rings 
treated with IL-6 or VEGF and do the same experiments. 
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5 The interaction of IL-6 with pericytes 
 
As previously discussed, pericytes are important regulators of vascular development, 
stabilisation, maturation and remodelling. Pericytes promote vessel stability and 
control vessel permeability by inducing endothelial cell-cell adhesions and tight 
junctions [138]. Loss of pericytes has been linked to different pathological conditions 
such as oedema, diabetic retinopathy and even embryonic lethality [135]. Studies 
have shown that loss of pericytes play a major role in the development of tumour 
metastasis [182, 183]. 
Pericytes play a major role in the type of angiogenesis stimulated in physiological and 
pathological conditions. In the presence of pericytes, the newly formed vasculature 
rapidly matures, becomes stable and stops proliferating. However, in some 
pathological conditions, blood vessels deficient of pericytes can undergo excessive 
sprouting which can ultimately lead to aberrant angiogenesis [135] .  
IL-6 has been previously shown to stimulate destabilised angiogenesis in models of 
rheumatoid arthritis [184]. However, the underlying mechanism involved in the 
induction of the aberrant angiogenesis by IL-6 has not been studied in detail and it is 
not known if this effect is only found in inflammatory disease. Therefore, in this 
chapter I was interested in investigating the morphology and maturation status of the 
vessels after treatment with IL-6 as compared to VEGF in the aortic ring assay, by 
determining the pericyte coverage around the vessels.  
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5.1 Lectin and α-SMA staining of mouse aortic ring vessels 
after treatment with VEGF and hIL-6 
 
Once I established that IL-6 can induce sprouting in the aortic ring assay and that 
IL-6 probably does not act via VEGF induction and signalling in the MLEC, I 
wanted to investigate how the differences in IL-6 and VEGF induced signalling could 
affect the morphology of vessels in the aortic ring assay. Therefore, I decided to stain 
the vessels for the endothelial cell marker BS1 lectin and pericyte marker α-SMA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Immunofluorescence staining of mouse aortic aortic rings after 
treatment with VEGF (30ng/mL) or hIL-6 (50ng/ml) over a course of 2 weeks.  
BS1 lectin-FITC (green) stains endothelial sprouts, anti-α-SMA-Cy3 (red) stains the 
pericytes/activated fibroblast and DAPI (blue) is for staining the nucleus. The images display the 
pericyte coverage (red) around the matured endothelial sprouts (green). Scale bar = 20µm 
 
VEGF (30ng/ml) 
     hIL-6 (50ng/ml) 
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Figure 5.1 shows the confocal images of the mouse aortic ring blood vessels treated 
with VEGF or hIL-6 stained for BS1 lectin for endothelial cells (green) and α-SMA 
for pericytes (red). The observations I made from these confocal images was that in 
the VEGF treated sprouts, the vessels seemed to be more organised compared to the 
IL-6 treated vessels which appeared to be more disorganised and chaotic. There also 
seemed to be more α-SMA staining around the vessels treated with VEGF compared 
to the vessels treated with hIL-6. This suggested that there was more maturation of 
vessels in the aortas treated with VEGF compared to hIL-6. This was an interesting 
observation because it fitted in with the study carried out in rheumatoid arthritis 
showing IL-6 could lead to formation of destabilised vasculature [184].  
I next decided to quantify this pericyte coverage by concentrating on the tip of the 
vessels in the aortic rings treated with VEGF or hIL-6. This was done to eliminate 
any false positive α-SMA staining, which could have resulted due to staining of 
activated fibroblasts (myofibroblasts), which are normally found near the stalk of the 
vessels.  
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Figure 5.2 Immunofluorescence staining of mouse aortic rings after 2 weeks 
treatment with VEGF (30ng/mL) or hIL-6 (50ng/ml).  
BS1 lectin-FITC (green) stains endothelial sprouts, anti-α-SMA-Cy3 (red) stains the pericytes and 
DAPI (blue) is for the nucleus. The images display the pericyte coverage (red) around the matured 
endothelial sprouts (green). Scale bar = 20µm 
Figure 5.2 shows confocal images of the tips of vessels treated with VEGF or hIL-6 
stained for BS1 lectin and α-SMA. As observed in Figure 5.1, there was good 
pericyte coverage in the vessels treated with VEGF and this was noticed in majority 
of the vessels. However, in case of the hIL-6 treated vessels, there were reduced 
pericyte coverage in majority of the vessels. There were also some cases in the hIL-6 
treated group where the pericytes seemed to be detaching from the vessels as shown 
in Figure 5.2.  
 
 
VEGF (30ng/ml) 
hIL-6 (50ng/ml) 
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Figure 5.3 Quantification of number of pericyte in the VEGF or hIL-6 treated 
mouse aortic ring vessels.  
Confocal images were taken of the tip of the vessels treated with VEGF (30ng/ml) or hIL-6 (50ng/ml) 
stained for BS1 lectin and α-SMA. The number of pericytes were counted 250microns from the tip of 
the vessels. * Represents statistical significance (p value < 0.004). Combined results from 3 
independent experiments (9 rings per condition). 
Figure 5.3 shows the quantification of the pericytes in the vessels treated with VEGF 
or hIL-6. The α-SMA staining was significantly lower in the hIL-6 treated aortic 
rings compared to the VEGF group. This showed less maturation of vessels treated 
with hIL-6 suggesting that these vessels could have weak tight junctions that could 
be leaky and permeable.  
5.2 Lectin and α-SMA staining of mouse aortic ring vessels 
after treatment with VEGF or mIL-6 
 
Once I established that there was less pericyte coverage after treatment with hIL-6 
compared with VEGF, I wanted to make sure that the effect I saw on pericytes with 
hIL-6 was not because I used hIL-6 in the mouse aortic ring assay. Therefore, in 
order to verify this effect of depletion of pericyte with IL-6 treatment, it was 
important to investigate the pericyte coverage after treatment of mouse aortic rings 
with mIL-6. 
      *   * 
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Figure 5.4 Immunofluorescence staining of mouse aortic rings after 2 weeks 
treatment with VEGF (30ng/mL) or mIL-6 (30ng/ml). 
BS1 lectin-FITC (green) stains endothelial sprouts, anti-α-SMA-Cy3 (red) stains the pericytes and 
DAPI (blue) is for the nucleus. The images display the pericyte coverage (red) around the matured 
endothelial sprouts (green). Scale bar = 20µm 
 
Figure 5.4 shows the confocal images of the tip of the vessels from mouse aortic rings 
treated with either VEGF or mIL-6 stained for BS1 lectin and α-SMA. As observed 
in Figure 5.2, there was good pericyte coverage in the vessels treated with VEGF. 
However, in case of the mIL-6 treated vessels, the staining was similar to the hIL-6 
treated vessels with diminished pericyte coverage around the vessels. As shown in 
Figure 5.4 there were also some cases in the mIL-6 treated group where the pericytes 
VEGF (30ng/ml) 
mIL-6 (30ng/ml) 
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were not closely associated with the vessels and they seemed to be detaching from the 
vessels.  
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Quantification of number of pericyte in the VEGF or mIL-6 treated 
mouse aortic ring vessels.  
Confocal images were taken of the tip of the vessels treated with VEGF (30ng/ml) or hIL-6 (50ng/ml) 
stained for BS1 lectin and α-SMA. The number of pericytes were counted 250microns from the tip of 
the vessels. * Represents statistical significance. ( p value < 0.002). Combined results from 2 
independent experiments (6 rings per condition).  
 
Figure 5.5 show the quantification of the pericytes in the vessels treated with VEGF 
or mIL-6. The α-SMA staining was significantly lower in the mIL-6 treated aortic 
rings compared to the VEGF group. This correlates with the findings of the hIL-6 
treated vessels indicating decreased maturation of vessels when treated with IL-6 
compared with VEGF. 
 
5.3 Lectin and α-SMA staining of rat aortic ring vessels 
after treatment with VEGF and rIL-6 
 
In order to further confirm the effects of IL-6 on pericyte coverage, I felt it was 
important to establish this finding in the rat aortic ring assay where I used rIL-6. As 
    * 
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stated in chapter 3, I started using the rat aortic ring assays because the success rate 
of these assays was higher than the mouse aortic ring assays.  
 
 
 
 
Figure 5.6 Immunofluorescence staining of rat aortic rings after 2 weeks 
treatment with VEGF (10ng/mL) or rIL-6 (10ng/ml) over a course.  
BS1 lectin-FITC (green) stains endothelial sprouts, anti-α-SMA-Cy3 (red) stains for the pericytes and 
DAPI (blue) is for the nucleus. The images display the pericyte coverage (red) around the matured 
endothelial sprouts (green). Scale bar = 20µm 
 
Figure 5.6 shows the confocal images of the tip of the rat aortic ring vessels treated 
with VEGF or rIL-6 stained for BS1 lectin and α-SMA. This again showed the 
differences in the pericyte coverage in the VEGF and rIL-6 treated aortic rings. The 
rIL-6 group not only seemed to have very few pericyte coverage but as witnessed 
VEGF (10ng/ml) 
rIL-6 (10ng/ml) 
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with the human and mouse IL-6 treated vessels the pericytes in the rIL-6 treated 
aortic rings seemed to be detached from the vessels.  
 
 
 
 
 
 
 
 
 
Figure 5.7 Quantification of number of pericyte in the VEGF or rIL-6 treated rat 
aortic ring vessels.  
Confocal images were taken of the tip of the vessels treated with VEGF (10ng/ml) or rIL-6 (10ng/ml) 
stained for BS1 lectin and α-SMA. The number of pericytes were counted 250microns from the tip of 
the vessels. * Represents statistical significance. (p value < 0.01). Combined results from 2 
independent experiments (5 rings per condition).  
 
Figure 5.7 shows the quantification of pericytes in the VEGF and rIL-6 treated aortic 
ring vessels. The quantification confirmed significantly lower number of pericyte 
coverage in the rIL-6 treated vessels compared with the VEGF. This again correlated 
with the findings of the human and mouse IL-6 aortic ring experiments.  
5.4 IL-6Rα expression on pericytes  
 
So far my study had shown that IL-6 can drive angiogenesis or sprouting in the aortic 
ring assay and that there was decreased vessel-associated pericytes in the IL-6 treated 
vessels compared to the VEGF treated ones. Therefore, my next aim was to 
investigate why there is a difference in the pericyte coverage in the IL-6 and VEGF 
treated vessels. To understand the mechanism involved in the depletion of pericytes 
in IL-6 treated group, it was important to first see if pericytes expressed IL-6Rα. 
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Figure 5.8 Confocal images of IL-6Rα  on pericytes in mouse aortic rings treated 
with VEGF (30ng/mL) or mIL-6 (30ng/ml).  
Aortic rings treated with VEGF or mIL-6 were stained for IL-6Rα (green), α-SMA (red) and DAPI 
(blue). Yellow shows the area of co-localisation of the IL-6Rα with the pericytes. Scale bar = 20µm 
 
Figure 5.8 shows staining of IL-6Rα on pericytes in the mouse aortic ring assay. The 
pericyte in both the VEGF and mIL-6 treated groups seemed positive for IL-6Rα, 
shown in yellow as a result of the green (IL-6Rα) and red (pericytes) co-localisation. 
There was more co-localisation in the VEGF treated group compared to the mIL-6 
treated groups and this could be due the presence of more pericytes in VEGF treated 
vessels. This result therefore confirms the existence of the IL-6Rα on pericytes.  
VEGF (30ng/ml) 
mIL-6 (30ng/ml) 
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In summary, this chapter showed that unlike VEGF, IL-6 could lead to aberrant 
angiogenesis with defective pericyte coverage in the aortic ring assay. This was 
established in human, mouse and rat aortic ring assays. Staining for IL-6Rα on 
pericytes and on endothelial sprouts (Chapter 4) showed positive expression of the 
receptor on both the cell types. Hence, the next step is to understand the mechanism 
by which IL-6 leads to defective pericyte coverage compared to VEGF. 
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6 The mechanism of differential effect of IL-6 
and VEGF on pericyte coverage of blood 
vessels 
 
In chapter 4, I found that VEGF did not signal via pSTAT3 and that IL-6 did not 
signal via pERK in MLEC. The aortic ring assay showed clear differences in the IL-6 
and VEGF-induced sprouting especially in terms of the morphology and maturation 
status of the vessels. This gave a further indication that IL-6 and VEGF might signal 
using different pathways and supports my hypothesis that ‘IL-6 drives aberrant 
angiogenesis independent of VEGF signalling’.  
Therefore, using MLEC as a model, I wanted to investigate alternative angiogenic 
signalling pathways that could be regulated by IL-6. I initially decided to use  MLEC 
to explore the Notch signalling pathway because of the previously known link of IL-6 
with the Notch ligand Jagged1 in ovarian cancer [185]. As mentioned earlier, a study 
conducted by Ralph Adams showed the opposing regulation of the Notch ligands 
Jagged1 and DLL4 on the endothelial cells [109]. The results showed that DLL4, 
which is present in the tip cells, can activate the Notch receptors in the stalk cell 
leading to maturation of the vessels. However, Jagged1 present in the stalk cell can 
antagonise the effects of DLL4 by blocking its binding to the Notch receptor and this 
leads to more of a tip phenotype characterised by excessive sprouting. VEGF has 
previously been shown to regulate this Notch-DLL4 signalling and thereby lead to 
activation of the downstream repressor gene Hey [109].  
Various studies have also shown that high levels of DLL4 on endothelial cells 
correlate with high levels of pericytes on vessels [142, 186]. Therefore, I decided to 
study the regulation of the Notch ligands Jagged1 and DLL4 in MLEC after 
treatment with VEGF or mIL-6. 
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Figure 6.1 Western blot analysis of the expression of Jagged1 and DLL4 in 
VEGF and mIL-6 treated MLEC.  
2x105 MLEC cells were plated and treated with control (PBS), VEGF or mIL-6 for 24 hours. The 
cells were then lysed and 20ng/ml of protein was used to detect the levels of Jagged1 and DLL4 using 
western blotting analysis. β-actin was used as loading control. This is typical of two independent 
experiments. This experiment was also repeated at 2 hours and 6 hours.  
 
Figure 6.1 shows the expression of the Notch ligands DLL4 and Jagged1 after 
treatment with VEGF or mIL-6. Mouse IL-6 induced more Jagged1 than VEGF and 
VEGF induced more DLL4 than mIL-6 in MLEC. Collectively these data confirm 
the findings of the opposing regulation of the Notch ligands Jagged1 and DLL4 in 
endothelial cells. Since the angiogenic ligand DLL4 is also reported to play a role in 
vessel maturation, these data give a possible insight into why there could be less 
pericyte coverage in the IL-6 treated vessels compared to the VEGF treated ones. 
As mentioned previously, induction of DLL4 via VEGF leads to activation of the 
downstream transcription factor Hey. Therefore, I tested the expression of Hey in 
the VEGF or mIL-6 treated MLEC. 
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Figure 6.2 Western blot analysis of the expression of Hey in VEGF or mIL-6 
treated MLEC.  
2x105 MLEC cells were plated and treated with control (PBS), VEGF or mIL-6 for 24 hours. The 
cells were then lysed and 20ng/ml of protein was used to detect the levels of Hey using western 
blotting analysis. β-actin was used as loading control. This is typical of two independent experiments. 
This experiment was also repeated at 2 hours and 6 hours. 
 
Figure 6.2 showed an increase in expression of Hey in the VEGF treated group but 
not in the mIL-6 or control treated groups. This further gives proof of the activation 
of the DLL4-Notch signalling in the MLEC after stimulation with VEGF but not 
with IL-6.  
Once I established the differential regulation of the angiogenic ligand Jagged1 and 
DLL4 being a possible explanation for the decreased level of pericyte in the IL-6 
treated group, I was then interested to look further into the mechanism and 
understand the reasons for the loose association of pericytes in the IL-6 treated 
vessels. It was at this point that I came across a study carried by Kayakabe et al, that 
showed a regulation of Angiopoeitin2 (Ang2) by IL-6 [184]. Angiopoeitin1 (Ang1) 
plays a key role in the attachment of the pericytes to the endothelium and Ang2 is 
known to be an antagonist of Ang1. Ang2 blocks the interaction between the Ang1 
on the pericytes and the Tie receptor on the endothelial cells [187]. I therefore 
wanted to study the regulation of Ang2 in MLEC after treatment with VEGF or 
mIL-6 
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Figure 6.3 Western blot analysis of the expression of Angiopoietin-2 in VEGF 
and mIL-6 treated MLEC.  
2x105 MLEC cells were plated and treated with control (PBS), VEGF or mIL-6 for 24 hours. The 
cells were then lysed and 20ng/ml of protein was used to detect the levels of Angiopoietin-2 using 
western blotting analysis. β-actin was used as loading control. This is typical of two independent 
experiments. This experiment was also repeated at 2 hours and 6 hours. 
 
Figure 6.3 shows the expression of Ang-2 in MLEC treated with VEGF or mIL-6 
after 24 hours. There is an increase in level of Ang-2 in the VEGF and mIL-6 treated 
MLEC, with mIL-6 inducing higher expression of Ang-2 compared to VEGF. This 
difference in expression of Ang-2 could be a possible reason for the altered 
maturation status observed in the aortic ring assay after treatment with VEGF or 
mIL-6.  
Next, I decided to look into N-cadherin which is another protein that is involved in 
endothelial-pericyte interaction [188]. As already mentioned, N-cadherins are 
glycoproteins that mediate calcium dependent cell-cell adhesion. A study also 
suggested that, N-cadherin deficiency leads to impaired pericyte recruitment [140]. 
This study showed that N-cadherin is not essential for endothelial migration or 
sprouting but it is required for the subsequent maturation of the endothelial sprouts. 
So, I wanted to investigate the effects of mIL-6 and VEGF on the expression of N-
cadherin in MLEC.   
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Figure 6.4 Western blot analysis of the expression of N-cadherin in VEGF and 
mIL-6 treated MLEC. 
 2x105 MLEC cells were plated and treated with control (PBS), VEGF or mIL-6 for 24 hours. The 
cells were then lysed and 20ng/ml of protein was used to detect the levels of N-cadherin using western 
blotting analysis. β-actin was used as loading control. This experiment was also repeated at 2 hours 
and 6 hours. 
 
Figure 6.4 shows the expression of N-cadherin in MLEC after treatment with mIL-6 
and VEGF. There was a slight decrease in the level of N-cadherin in the mIL-6 
treated MLEC compared to the control. However, in the VEGF treated group there 
was an increase in expression of N-cadherin compared to the mIL-6 and the control 
group. This result correlated with the findings of the previous study and adds a 
possible explanation for the impaired interaction between the endothelial cells and 
pericytes in the presence of IL-6 [140]. This is however a preliminary result and it 
needs to be repeated for further confirmation.  
Unravelling the mechanisms of action of VEGF and IL-6 on MLEC showed 
differential regulation of the Notch ligands Jagged1 and DLL4 by IL-6 and VEGF 
in MLEC. This correlated with the known role of DLL4 in vessel maturation and 
Jagged1 in excessive sprouting. The VEGF induced activation of the downstream 
repressor gene Hey also correlated with the known regulation of DLL4-Notch 
signalling by VEGF. Investigating more into mechanism of pericyte detachment 
showed a positive regulation of Ang-2 and a negative regulation of N-cadherin by IL-
6 in MLEC. This also gave a possible explanation for the detachment of pericytes on 
the IL-6 treated vessels. 
Although technically challenging, I would aim to extract protein from the aortic rings 
treated with IL-6 or VEGF and do the same experiments. 
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7 Study the effects of VEGFR inhibitor on 
aortic ring assay and on MLEC 
 
In the previous chapter, experiments on mechanism of action of VEGF and IL-6 in 
MLEC showed differential regulation of the Notch ligands and Ang2 by IL-6 and 
VEGF. These findings along with the differences in pericyte coverage observed after 
treatment with VEGF or IL-6 in the aortic ring assay (chapter 5), further suggest 
that these pathways don’t depend on each other for their angiogenic effects. 
Therefore, I wanted to investigate the angiogenic effects of IL-6 in the presence of a 
VEGFR inhibitor. 
In this chapter I will present some preliminary data from studies with a VEGFR 
inhibitor in the aortic ring assay and in MLEC. The VEGFR inhibitor used for my 
study was cediranib, which is a VEGFR2 inhibitor that is currently used in clinical 
trial in various cancers. Cediranib was recently used in a Phase III clinical trial in 
ovarian cancer patients and it prolonged progression free survival by 3 months 
compared to standard chemotherapy alone [189]. 
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7.1 To study the angiogenic effects of IL-6 using a VEGFR 
inhibitor in the aortic ring assay 
 
The first set of experiments that I carried out using the VEGFR inhibitor, which 
further confirmed IL-6 could drive angiogenesis independent of VEGF signalling, 
were in the aortic ring assay. First I carried out a dose response experiment with 
cediranib to identify the optimal dose needed to inhibit sprouting in the VEGF 
treated group. Using the aortic ring assay, I wanted to investigate if IL-6 can still 
induce sprouting in the aortic ring assay in the presence of a VEGFR inhibitor, 
cediranib. 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 Mean number of sprouts in aortic rings treated with medium, VEGF, 
rIL-6, VEGF + cediranib (VEGFRi) and rIL-6 + VEGFRi. 
Aortas removed following cervical dislocation of a 180-200g rats were treated with optimem medium 
containing 1% FCS with 10ng/ml VEGF (R&D) or 10ng/ml rIL-6 (R&D), 10nM VEGFRi + 
VEGF/rIL-6 over a course of 2 weeks. The medium was changed every 3 days. The rings were imaged 
using phase contrast microscopy and microvessel outgrowth was counted and quantified (p value < 
0.002 between medium and VEGF), (p value < 0.0004 between medium and rIL-6), (p value < 0.0054 
between VEGF and VEGF +VEGFRi), (p value < 0.24 between rIL-6 and rIL-6 + VEGFRi). 
*Represents statistical significance. This result represents typical of two independent experiments.  
 
Figure 7.1 shows the result of the aortic ring assay treated with VEGF and rIL-6 in 
combination with the VEGFRi. As expected, there were a significantly higher 
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number of sprouts in the VEGF and rIL-6 treated group as compared to the medium. 
In the terms of the VEGF + VEGFRi treated group, the VEGFRi inhibited sprouting 
in some of the aortas and even the aortas that managed to overcome the inhibition 
had significantly lower number of sprouts as compared to the VEGF alone treated 
group. However, in case of the rIL-6 + VEGFRi group, most of the aortas were able 
to overcome the inhibition of the VEGFRi. Even in terms of number of sprouts, there 
were not any significant difference between the rIL-6 and rIL-6 + VEGFRi group. 
This further supports the findings from the MLEC suggesting IL-6 and VEGF 
signalling might not be dependent on each other for its angiogenic effects. 
7.2 The effects VEGFRi on pSTAT3 induction in the MLEC 
 
I then decided to investigate the effects of the VEGFRi on MLEC after treatment 
with recombinant VEGF or mIL-6. I was interested in exploring this because 
elevated levels of IL-6 in patient plasma has shown to correlate with anti- angiogenic 
therapy resistance in various cancers [159, 160]. However, the effects of VEGFRi on 
IL-6 signalling on endothelial cells are still unknown.  
 
Figure 7.2 Western blot analysis of the expression of pSAT3 in VEGF, mIL-6, 
cediranib (VEGFRi) treated MLEC.  
2x105 MLEC cells were plated and treated with control (PBS), VEGF (30ng/ml), mIL-6 (30ng/ml), 
VEGFRi (100nM), VEGF + VEGFRi and mIL-6 + VEGFRi for 24 hours. The cells were then lysed 
and 20ng/ml of protein was used to detect the levels of pSTAT3 and STAT3 using western blotting 
analysis. β-actin was used as loading control. 
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The western blot shown in Figure 7.2 shows the expression of pSTAT3 after 
treatment with recombinant mIL-6, VEGF, VEGFRi +/- VEGF or rIL-6. As 
expected, mIL-6 treatment resulted in upregulation of pSTAT3 in MLEC, however 
treatment with mIL-6 and VEGF led to a slight decrease in pSTAT3 levels. This 
might suggest VEGF has an inhibitory effect on IL-6 downstream signalling in 
endothelial cells. However, the interesting finding from this western blot analysis was 
the increased expression of pSTAT3 observed in the mIL-6 + VEGFRi group as 
compared to the mIL-6 group. This upregulation of pSTAT3 in the presence of IL-6 
on MLEC was also observed with other VEGFR inhibitors i.e. Brivanib and 
Apatanib (data not shown). This suggests endothelial cell inhibition of VEGFR in 
tumours expressing IL-6 can lead to upregulation of pSTAT3. With reference to 
Chapter 5, this finding implies a vasculature with very defective pericyte coverage 
and increased chances of metastasis after treatment with VEGFRi. This result 
therefore suggested a potential for combination of VEGFR and IL-6 inhibitor for 
targeting tumours with high levels of IL-6.  
 
7.3 The effects VEGFRi + rIL-6 on pericyte coverage in 
aortic ring assay 
 
I was then interested in studying the effects of VEFFRi on pericyte coverage in aortic 
ring vessels treated with rIL-6. I wanted to investigate this because of the previous 
finding, which suggested VEGFRi inhibition on endothelial cells treated with 
recombinant IL-6 leads to increased expression of pSTAT3 compared to recombinant 
IL-6 alone.  
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Figure 7.3 Immunofluorescence staining of aortic rings after treatment with 
VEGF 10ng/ml, rIL-6 or rIL-6 10ng/ml + VEGFRi 10nM over a course of 2 
weeks.  
BS1 lectin-FITC (green) stains endothelial sprouts, α-SMA-Cy3 (red) stains the pericytes and DAPI 
(blue) is for staining the nucleus. The images display the pericyte coverage (red) around the matured 
endothelial sprouts (green). Scale bar = 20µm 
            
              VEGF 10ng/ml  
            
              rIL-6 10ng/ml  
            
  rIL-6 10ng/ml + VEGFRi 10nM   
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Figure 7.3 show the pericyte (red) coverage on the aortic ring vessels (green) after 
treatment with VEGF, rIL-6 and rIL-6 + VEGFRi. These preliminary results show 
good pericyte coverage on the VEGF treated vessels as expected and poor or 
detached pericyte coverage on the rIL-6 treated vessels. However in case of VEGFRi 
+ rIL-6 treated vessels there are hardly any pericytes associated with the vessels 
compared to the other two groups. This further supported the pSTAT3 upregulation 
observed in the MLEC after treatment with the VEGFR inhibitor. 
A summary of the proposed mechanism of action of VEGFRi on endothelial cells in 
the presence of IL-6 is shown in Figure 7.4. This summary is based on studies, which 
have reported that sustained Src inhibition as a result of VEGFR inhibition could 
lead to increase in pSTAT3 expression [190]. My preliminary data on MLEC also 
correlated with this study and showed a compensatory effect on pSTAT3 as a result 
of Src inhibition using the VEGFR inhibitor (data not shown). This increased 
pSTAT3 expression as a result of Src inhibition leads to even weaker perciyte 
coverage as on vessels as shown in Figure 7.3. 
 
 
 
 
 
 
 
 
 
 
Figure 7.4 Showing the proposed mechanism of action of VEGFi on endothelial 
cells in the presence of IL-6.  
VEGFRi leads to inhibition of pSrc, which results in increased expression of pSTAT3 and even 
weaker pericyte coverage.  
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All the above shown results in this section are preliminary data and therefore they 
need to be repeated and carried out at different time points with different doses of 
inhibitors to fully validate these findings. However, they do give further evidence that 
IL-6 and VEGF have different mechanism of action on endothelial cells. The 
VEGFRi induced upregulation of pSTAT3 in the presence of IL-6 also suggest a 
compensatory effect on IL-6 signalling upon VEGFR inhibition in the endothelial 
cells. This therefore suggests a potential for combining VEGFR inhibitors with anti-
IL-6 agents in IL-6 driven tumours.  
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8 Study the effects of the anti-IL-6 antibody on 
pericyte coverage in IGROV-1 xenografts 
 
In parallel to the ex vivo and in vitro work that was carried to understand the effects 
and mechanism of IL-6 and VEGF induced angiogenesis, I was also interested in 
studying the effects of an anti-IL-6 antibody in ovarian cancer xenografts. This is 
because tumour cells use blood vessels as a route to spread during metastasis and also 
the growth of the primary tumour depends on the formation of the tumour 
vasculature. There are often abnormalities within the primary tumour that lead to 
increased perfusion and escape of the tumour cells into the circulation. The abnormal 
vasculature is often characterised by leaky vessels displaying gaps in the endothelium 
[191, 192]. This not only leads to increased metastasis but also increased drug 
resistance due to poor drug delivery to the organs.  
As previously described, IL-6 is linked to poor prognosis in ovarian cancer patients 
[35]. A recent study in prostate cancer showed endothelial cells enhance prostate 
cancer metastasis via IL-6 [193]. Treatment of ovarian cancer xenografts with an 
anti-IL-6 antibody not only led to reduction in vasculature but also resulted in 
normalisation of the blood vessels [35]. This suggests that IL-6 production in the 
tumour microenvironment could contribute to the destabilised and chaotic 
vasculature. 
Therefore, in this chapter I was interested in investigating the pericyte coverage in 
IL-6 producing IGROV-1 ovarian cancer xenografts after treatment with the anti-IL-
6 antibody. I also wanted to investigate some of mechanisms previously studied in the 
MLEC in the vivo tumour samples after treatment with the anti-IL-6 antibody.  
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8.1 Staining for Lectin, α-SMA and DAPI in anti-IL-6 
treated IGROV-1 xenografts 
 
Mice injected intraperitoneally with IGROV-1 cells (IL-6 producing cells) were 
treated with either 20mg/kg of IgG control antibody or anti-IL-6 antibody. To 
visualise the vasculature the terminal animals were anaesthetised with isoflourane 
and injected with FITC conjugated lectin via tail vein 3 min before animals were 
perfused with 4% paraformaldehyde. In these lectin stained frozen tumour sections, I 
decided to stain for pericytes with a widely used marker for pericytes i.e. α-SMA. 
This was carried out to compare the differences in the pericyte coverage of the 
tumour vessels in the IGROV-1 control and anti-IL-6 treated tumours.  
Figure 8.1 Confocal images of IGROV-1 control antibody and anti-IL-6 treated 
IGROV-1 tumours stained for lectin (red), α-SMA (green) and DAPI (blue).  
The control antibody (20mg/kg) and anti-IL-6 (20mg/kg) treated mice were injected with lectin via tail 
vein 3 min before fixing. This was followed by snap freezing, sectioning of the tumour and staining for 
α-SMA (green). Images of the stained sections were taken using confocal microscopy (Scale bar = 
10microns) 
Figure 8.1 shows the IGROV-1 xenograft tumours treated with an anti-IL-6 
antibody stained for blood vessels and pericytes using lectin and α-SMA. 
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 In the IGROV-1 control group there were very few pericytes around the vessels and 
this was noted in majority of the cases. Also, the vessels in the control group seemed 
to be more disorganised and discontinuous, which might suggest a leaky vasculature. 
However, in the anti-IL-6 treated group there seemed to be good pericyte around the 
tumour vessels indicating mature vasculature. These results correlate with the 
findings from the aortic ring assay where the recombinant IL-6 led to decreased 
vessel maturation. 
Figure 8.2 Showing the staining for Lectin (red), α-SMA (green) and DAPI 
(blue) on IGROV-1 control antibody and anti-IL-6 treated tumours.  
The control and anti-IL-6 treated mice were injected with lectin via tail vein 3 min before fixing. This 
was followed by snap freezing, sectioning of the tumour and staining for α-SMA (green). Images of 
the stained sections were taken using confocal microscopy (Scale bar = 10microns) 
Figure 8.2 shows the IGROV-1 control antibody and anti-IL-6 treated tumours 
stained for blood vessels and pericytes using lectin and α-SMA. This figure is shown to 
highlight the fact that in some cases especially with the IGROV-1 control tumour 
sections, the pericytes seemed to be loosely attached or detaching from the vessels, 
however this was hardly noticed with the anti-IL-6 treated tumours. This again links 
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with the finding from the aortic ring assay where treatment with recombinant IL-6 led 
to detachment of pericytes from the vessels. 
 
 
 
 
 
 
 
 
 
 
Figure 8.3 Quantification of α-SMA on tumour vessels treated with either 
IGROV-1 control antibody or anti-IL-6 antibody.  
The control and anti-IL-6 treated mice were injected with lectin via tail vein 3 min before fixing. This 
was followed by snap freezing, sectioning of the tumour and staining for α-SMA. The blinded images 
from two independent experiments (n=6 per group) were quantified according to the 4 different 
criteria i.e. good coverage, medium coverage, poor coverage and detached by two independent 
reviewers. (IGROV-1 control vs anti-IL-6 treated, chi square test p value <0.001) 
 
Figure 8.3 shows the quantification of the α-SMA staining in the IGROV-1 control 
antibody and anti-IL-6 antibody treated tumours. In the IGROV-1 control antibody 
treated tumours 44% of the vessels showed poor staining of α-SMA and 35% of the 
vessels had detached pericytes. The remaining 21% of vessels had either good or 
medium α-SMA staining. However, in case of the anti-IL-6 antibody treated tumours, 
66% of the vessels showed good pericyte coverage and 17% of the vessels had medium 
pericyte coverage according to the α-SMA staining observed. Only the remaining 16% 
of vessels showed either poor or detached pericyte coverage. This observation again 
correlates with the findings from the aortic ring assay, where IL-6 led to poor or 
detached pericyte coverage.  
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Since α-SMA can also stain for activated fibroblasts in the tumour vasculature it was 
important to use another marker to confirm the differences in the pericyte staining 
observed with the control and the anti-iL-6 treated IGROV-1 tumours.  
8.2 Staining for Lectin, NG2 and DAPI in anti-IL-6 treated 
IGROV-1 xenografts 
 
There is no known single entirely specific marker for pericytes, therefore generally 
two or more pericyte markers are used alongside endothelial cell staining. Neural 
glial antigen 2 (NG2) is a proteoglycan that is expressed on pericytes in the tumour 
vasculature [194]. Therefore, I decided to stain the IGROV-1 tumour sections with 
NG2. 
Figure 8.4 Confocal images of IGROV-1 control antibody and anti-IL-6 treated 
IGROV-1 tumours stained for lectin (red), NG2 (green) and DAPI (blue). 
The control and anti-IL-6 treated mice were injected with lectin via tail vein 3 min before fixing. This 
was followed by snap freezing, sectioning of the tumour and staining for NG2 (green). Images of the 
stained sections were taken using confocal microscopy (Scale bar = 10microns) 
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Figure 8.4 shows the IGROV-1 control tumours stained for blood vessels and 
pericytes using lectin and anti-NG2. The NG2 staining in the tumour endothelium in 
the IGROV-1 control and anti-IL-6 treated IGROV-1 tumours are similar to the α-
SMA staining observed in Figure 7.1. The IGROV-1 control tumours seems to have 
poor pericyte coverage as compared to the anti-IL-6 treated tumours.  
 
Figure 8.5 Showing the staining for Lectin (red), NG2 (green) and DAPI (blue) 
on anti-IL-6 treated IGROV-1 tumours.  
The control and anti-IL-6 treated mice were injected with lectin via tail vein 3 min before fixing. This 
was followed by snap freezing, sectioning of the tumour and staining for α-SMA (green). Images of 
the stained sections were taken using confocal microscopy (Scale bar = 10microns) 
Figure 8.5 shows the IGROV-1 control tumours stained for blood vessels and 
pericytes using lectin and anti-NG2.  As witnessed with the α-SMA staining in Figure 
7.2, NG2 staining also showed loose attachment of pericytes with the blood vessels in 
the some of the IGROV-1 control tumours. This implicated the possible involvement 
of some angiogenic genes that is regulated by IL-6 in the detachment of pericyte from 
the endothelium. 
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Figure 8.6 Quantification of NG2 on tumour vessels treated with either IGROV-
1 control antibody or anti-IL-6 antibody.  
The control and anti-IL-6 treated mice (n=3) were injected with lectin via tail vein 3 min before fixing. 
This was followed by snap freezing, sectioning of the tumour and staining for NG2. The blinded 
images from two independent experiments (n=6 per group) were quantified according to the 4 
different criteria i.e. good coverage, medium coverage, poor coverage and detached by two 
independent individuals. (IGROV-1 control vs Anti-IL-6 treated, chi square test p value <0.001) 
 
Figure 8.6 shows the quantification of the NG2 staining in the IGROV-1 control 
antibody and anti-IL-6 antibody treated tumours. According to the NG2 staining in 
the IGROV-1 control antibody group, 62.5% of the vessels had detached pericyte 
coverage and 18% of the vessels had poor pericyte coverage. The results were similar 
to the α-SMA staining with majority of the vessels showing poor or detached pericyte 
coverage, however there were almost twice the number of detached pericytes in the 
NG2 stained vessels than in the α-SMA stained vessels. This might therefore suggest 
that α-SMA staining might have picked up some activated fibroblast bound to the 
tumour vasculature thereby reducing the number of detached pericytes. However in 
case of the anti-IL-6 treated vessels, the NG2 staining were similar to the α-SMA 
staining with 75% of the vessels showing good pericyte coverage and 15% with 
medium pericyte coverage. Only 10% of the vessels had poor or detached pericyte 
coverage.  
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8.3  Immunohistochemistry staining of Jagged1, DLL4 and 
Ang2 in IGROV- 1 xenografts 
 
It was important to investigate the mechanism previously explored in the MLEC cells 
(Chapter 6) regarding the regulation of the angiogenic factors by IL-6. This included 
looking at the expression of Jagged1, DLL4 and Ang2 in the IGROV-1 control and 
the anti-IL-6 treated tumours.  
 
 
Figure 8.7 Jagged1, DLL4 and Ang-2 staining on IGROV-1 control antibody and 
anti-IL-6 treated mouse tumours.  
The tumour sections collected from mice treated with either 20mg/kg of control antibody or anti-IL-6 
antibody were paraffin fixed and cut into sections. The slides were then deparaffinised and stained 
with rabbit IgG control, Jagged1, DLL4 and Ang2 antibodies overnight at 4°C. The slides were then 
left for 2 hours with biotinylated anti-rabbit secondary antibody. Images were taken from two 
independent experiments using X40 magnification. 
40X 40X 40X 
40X 40X 40X 
40X 40X 40X 
       IgG Control      Control Antibody      Anti-IL-6 Treated 
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Figure 8.7 shows the staining for Jagged1, DLL4 and Ang-2 in the IGROV-1 
control and anti-IL-6 treated tumour sections. As previously reported, Jagged1 
staining is weaker in the anti-IL-6 treated group as compared to the control [35]. In 
terms of DLL4 the opposite was observed, there were more intense DLL4 staining in 
the malignant and stromal components in the anti-IL-6 treated group as compared 
with the control. Ang-2 was similar to the Jagged1 staining with weaker expression 
in the anti-IL-6 treated tumours as compared to the control. These findings further 
confirm the regulation of Jagged1 and Ang-2 by IL-6 and also suggest a possible 
explanation for the decreased pericyte coverage observed in the IGROV-1 control 
tumours.  
 
 
 
Figure 8.8 Quantification of Jagged1, DLL4 and Ang2 on mouse tumours treated 
with either IGROV-1 control antibody or anti-IL-6 antibody.  
The tumours sections collected from mice treated with either 20mg/kg of control antibody or anti-IL-6 
antibody were paraffin fixed and cut into sections. The slides were then stained for Jagged1, DLL4 or 
Ang2. Images were taken from 3 mouse sections per group using X40 magnification. The blinded 
images from two independent experiments were quantified according to the following scoring system 
(1 = little staining, 2 = faint partial staining, 2.5 = moderate staining, 3 = strong staining) by two 
independent reviewers.  
 
Figure 8.8 shows the quantification of Jagged1, DLL4 and Ang2 staining using the 
above mentioned scoring criteria i.e. 1, 2, 2.5 and 3 with 1 being the faintest and 3 
being the strongest. In the IGROV-1 control antibody group majority of the Jagged1 
staining scored either 2 or 3, however in case of the anti-IL-6 treated group most of 
the Jagged1 staining only scored 1 or 2. The staining was opposite for DLL4 with 
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the entire control antibody treated group scoring the faintest 1 and the anti-IL-6 
treated scoring 2 or 3. The Ang2 scoring was similar to the Jagged1 staining with 
majority of the control antibody tumours scoring 3 and the anti-IL-6 treated sections 
only scoring 1 or 2.  
8.4 Analysis of the gene expression data set from the HGSC 
patient biopsies 
 
I was then interested in looking into the gene expression dataset from HGSC patient 
biopsies to find any correlations with my in vitro and in vivo analysis. Therefore, gene 
expression data from 285 ovarian cancer biopsies from the AOCS (Australian 
Ovarian Cancer Study) dataset along with 245 samples obtained by merging two 
other publicly available datasets were ranked for expression of IL-6 pathway genes. 
Then 50 samples with the highest (high IL-6) and 50 samples with the lowest (low 
IL-6) levels of expression were selected and from that a list was generated of the 
differentially expressed genes between the high and low IL-6 samples [35]. These 
differentially expressed genes were then associated with various pathways and 
processes as shown below.  
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Figure 8.9 Heat map generated from the bioinformatics analysis of IL-6 pathway 
carried out in ovarian cancer patients.  
A shows the differentially expressed genes from the high and low IL-6 samples were 
associated with various pathways and processes i.e. Angiogenesis, Apoptosis, Cell 
Cycle/proliferation and Immune response/ Inflammation. B indicates two of the angiogenic 
genes positively correlated with high IL-6 pathway expression. 
Figure 8.9A shows the differentially expressed genes between the high and low IL-6 
samples linked with the following pathways and processes i.e. Angiogenesis, 
Apoptosis, Cell Cycle/proliferation and Immune response/ Inflammation. Significant 
associations were found between the high IL-6 pathway gene expression and with 
various processes including angiogenesis. 8.9B shows that the high IL-6 pathway 
expression also correlated positively with genes that were reduced by the anti-IL-6 
antibody treatment in the in vivo IGROV-1 xenografts  i.e. Jagged1 and Ang2.  
Gene symbol Gene description P value 
ANGPT2 Angiopoietin2 0.015 
JAG1 Jagged1 0.001 
A 
B 
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Finally, my studies so far on the differential regulation of IL-6 and VEGF on 
endothelial cells and the mechanism of action of VEGFR inhibitor on downstream 
IL-6 signalling have indicated a potential for the combination of anti-IL-6 antibody 
with the VEGFR inhibitor. Therefore, to sum up my study, I was interested in 
investigating the effects of combining an anti-IL-6 antibody with the VEGFR 
inhibitor in an IL-6 producing ovarian cancer cell line.  
8.5 Study the effect of VEGFRi +/- anti-IL-6 antibody on 
pSTAT3 expression in IGROV-1 
 
I wanted to investigate the effect of VEGFRi +/- anti-IL-6 antibody on pSTAT3 
expression in IGROV-1 cells. This was carried out to find out if VEGFR inhibition 
leads to further upregulation of pSTAT3 in malignant cells expressing high levels of 
IL-6. 
 
 
 
 
 
 
Figure 8.10 Western blot analysis of the expression of pSAT3 in IGROV-1 
treated with Anti-IL-6 and VEGFRi.  
2x105 IGROV-1 cells were plated and treated with 10ug/ml Anti-IL-6, 100nM VEGFRi and Anti-IL-6 
+ VEGFRi for 24 hours. The cells were then lysed and 20ng/ml of protein was used to detect the levels 
of pSTAT3 and STAT3 using western blotting analysis. β-actin was used as loading control. 
Figure 8.10 shows the western blot analysis of pSTAT3 in IGROV-1 cells after 
treatment with anti-IL-6 and VEGFRi. These preliminary results show a slight 
decrease in pSTAT3 expression after treatment with an anti-IL-6 antibody as 
compared to control. However, treatment with VEGFRi inhibitor led to further 
decrease in expression of pSTAT3 and VEGFRi + anti-IL-6 antibody led to almost 
abolishment of pSTAT3 levels. This was very interesting because this showed that 
the VEGFR inhibitor had different effect on malignant and endothelial cells in the 
presence of IL-6.  
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In overall, using this in vivo chapter, I was able to confirm the observations I made in 
the previous ex vivo and in vitro chapters regarding the type of angiogenesis stimulated 
by IL-6 and its possible mechanisms of actions. The IGROV-1 xenograft study also 
showed it was possible to restore the pericyte coverage in the vasculature by 
treatment with an anti-IL-6 antibody. The HGSC patient gene expression dataset 
gave a further confirmation for the mechanistic findings regarding the regulation of 
Jagged1 and Ang2 by IL-6. This along with the findings from the previous chapter 
on VEGFR inhibitor further suggests the potential for combining VEGFR inhibitor 
with an anti-IL-6 agent. The combination therapy will be beneficial if VEGFR 
inhibition leads to upregulation of pSTAT3 in IL-6 expressing tumours thereby 
further leading to aberrant angiogenesis with poor pericyte coverage. Hence, 
combination with anti-IL-6 agents will help restore the pericyte coverage and help in 
tissue perfusion, limit metastasis and increase drug delivery.  
 136 
9 Discussion & Plans for Future Work 
 
9.1 Effects of IL-6 on normal and tumour angiogenesis 
 
The pleiotropic cytokine IL-6 has been implicated in angiogenesis in diseases such as 
stroke, rheumatoid arthritis and various cancers [50, 184, 195]. Despite this 
evidence, to our knowledge there has been no in depth investigation undertaken to 
study the direct effects of IL-6 on endothelial cells. This thesis has presented the 
findings from an ex vivo model of angiogenesis along with a number of functional and 
mechanistic in vitro studies in the MLEC cells. These experiments were conducted in 
parallel with an IGROV-1 xenograft study and analysis of the HGSC patient gene 
expression datasets to find correlations with the ex vivo and in vitro findings. The 
experiments were undertaken to answer the following questions.. 
1) Does IL-6 have direct angiogenic effects on endothelial cells? 
2) What are the differences in IL-6 and VEGF induced angiogenesis in the   
aortic ring assay? 
3) What are the mechanisms of action of IL-6 on endothelial cells?  
4) What is the effect on the ovarian cancer vasculature after treatment with an 
anti-IL-6 antibody? 
5) Does this study suggest any possible combination therapy to target with an 
anti-IL-6 antibody? 
 
In this chapter, I aim to discuss the extent to which this research has answered these 
questions addressed above and outline future studies that will be conducted as a 
result of this thesis. 
9.1.1 Does IL-6 have direct angiogenic effects on endothelial cells?  
 
The primary objective of the ex vivo study was to investigate if recombinant IL-6 can 
be angiogenic and lead to endothelial sprouting. Using the aortic ring assay, I was 
able to show that IL-6 alone can induce sprouting of vessels at concentrations similar 
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to VEGF. I used the number and length of sprouts as the two parameters to examine 
the angiogenic potency of IL-6 compared to VEGF. The results of my study showed 
no significant difference in the two parameters suggesting IL-6 is almost as potent as 
VEGF in inducing sprouting in the aortic ring assay. This finding was further 
confirmed with recombinant human, mouse and rat IL-6 in mouse and rat aortic ring 
assays.  
Alongside this, in vitro studies were conducted in MLEC cells to study the functional 
and mechanistic effects of IL-6 as an angiogenic agent. My findings confirmed 
previous studies indicating IL-6 can drive endothelial proliferation and migration 
[163, 164]. In addition to this, the MLEC line was used to study the downstream 
mechanism via which IL-6 drives angiogenesis. This was mainly carried out to 
understand if the angiogenic effects observed with IL-6 were due to a response via 
VEGF and if the two pathways are dependent on each other for signalling in MLEC. 
Investigating the direct downstream targets of IL-6 and VEGF i.e. pSTAT3 and 
pERK suggested that the two pathways are independent of each other for signalling 
in the MLEC. 
9.1.2 What are the differences in IL-6 and VEGF induced 
angiogenesis in the aortic ring assay? 
 
Further exploration of the results from the ex vivo studies led to the most interesting 
observation of the study.  This finding came from the confocal images of aortic ring 
vessels stained for lectin and α-SMA, which showed a striking difference in the 
pericyte coverage of the vessels treated with recombinant VEGF and IL-6. 
Quantification of this staining later showed a significantly reduced number of 
pericytes in the IL-6 treated vessels as compared to the VEGF treated ones. Another 
interesting observation made from the confocal images was of the detachment of 
pericytes in some of the IL-6 treated vessels. The observations relating to pericytes 
and IL-6 have clinical implications in malignant and other diseases especially as 
studies in various cancers suggest that pericyte depletion leads to increased 
metastasis in tumours [138, 182, 183].  
 138 
The role of pericytes in the tumour vasculature is controversial [183]. Whilst a 
normalised, functional and perfused vasculature could enhance tumour growth by 
providing oxygen and nutrients to the primary tumour, destabilised, non-functional 
and permeable vasculature can enhance metastasis and chemoresistance. This may be 
why approaches of treating cancers with an anti-VEGF agent that targets the 
immature vasculature and then combining it with an agent such as a PDGFRβ 
inhibitor that affects the mature vasculature, have not shown much promise [151].  
This is also shown in various studies such as the one carried out in invasive breast 
cancer, where low pericyte coverage correlated with decreased patient survival. The 
study showed that depletion in pericytes inhibited tumour growth but lead to 
formation of defective tumour vasculature and increased metastasis [183]. 
Therefore, the sustained tumour vascular normalisation concept proposes the idea of 
restoring the functionality of the vessels in the tumour rather than disrupting them. 
This approach will improve perfusion and oxygenation and counteract the genes 
controlling hypoxia driven epithelial-mesenchymal transition and dissemination that 
would trigger the metastatic switch [196, 197]. 
9.1.3 What are the mechanisms of action of IL-6 on endothelial cells?  
 
It was important to understand the mechanism involved in inducing this immature 
vasculature phenotype in the IL-6 treated vessels. MLEC were used to understand 
the downstream mechanisms involved in inducing IL-6 mediated angiogenesis. My 
previous studies in chapter 4 on direct downstream VEGF and IL-6 targets 
suggested a possible differential mechanism of action of IL-6 compared to VEGF. 
Hence, I was interested in investigating other signalling pathways that were known 
to be associated with IL-6 signalling. Exploring the regulation of the Notch ligands, 
Jagged1 and DLL4, indicated a positive regulation of Jagged1 by IL-6 and DLL4 by 
VEGF in the MLEC.  For further confirmation, I investigated the downstream 
activation of Hey in the presence of VEGF or IL-6 and the positive Notch-DLL4 
interaction was confirmed in the VEGF treated MLEC.  In terms of future 
experiments, exploring the regulation of fringe family members which are involved in 
the glycosylation and activation of Notch-DLL4 signalling would give further 
validation for mechanism of action of IL-6 and VEGF in MLEC [108, 109].  
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There has been a lot of debate about the role of these Notch ligands in pericyte 
differentiation and formation. An earlier study suggested Notch-3 and Jagged1 to be 
important for differentiation of pericytes [198]. Apart from this finding, the majority 
of studies have shown endothelial DLL4 to play a critical role in pericyte formation 
during normal and tumour angiogenesis [142, 186, 199]. Inhibition of DLL4 
signalling in vivo induced proliferation of immature vessels and resulted in poor tissue 
perfusion [143]. Even the recent study with the DLL4 inhibitor MEDI0639 in 
human endothelial cell angiogenesis assay promoted vessel formation with reduced 
smooth muscle actin positive pericytes [130]. The results obtained from exploring 
Notch signalling in MLEC after treatment with VEGF or IL-6 fit with the majority 
of the published data. My results also show a correlation between endothelial DLL4 
expression and pericyte coverage in the VEGF treated vessels.  
Further exploring the mechanism of action of IL-6 in MLEC led to the investigation 
of Ang/Tie signalling. Ang2, as previously mentioned, is involved in detaching 
pericytes from the endothelial cells. Ang2 was also regulated by IL-6 and promoted 
destabilised vasculature in models of rheumatoid arthritis [184]. My findings showed 
increased Ang2 expression in the IL-6 treated MLEC as compared to the VEGF 
treated group. This gave an insight for the possible mechanism of detachment of 
pericytes from some of the IL-6 treated vessels in the aortic ring assay. This was 
again an interesting finding in the study because Ang2 expression was shown to 
correlate with metastasis in various cancers [150].  
9.1.4 What is the effect on the ovarian cancer vasculature after 
treatment with an anti-IL-6 antibody? 
 
The in vivo experiments were conducted to study the effects of an anti-IL-6 antibody 
on pericyte coverage in IGROV-1 xenografts (IGROV-1 cells constitutively produce 
IL-6). There were very few pericyte-associated vessels in tumours in the IGROV-1 
control group. However, treatment with an anti-IL-6 antibody led to a significant 
increase in pericyte associated vessels suggesting blocking IL-6 in tumours can lead 
to restoration of normalised vasculature. Immunohistochemistry analysis of Jagged1, 
DLL4 and Ang-2 in the IGROV-1 control and anti-IL-6 treated tumours showed a 
regulation of Jagged1 and Ang2 by IL-6. This again correlated with the data from 
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the previous findings of my lab and also with the results obtained from the MLEC 
study [35].  
However, recent studies by Domcke et al, questioned the use of IGROV-1 for further 
research in HGSCs [200].  This study compared copy number changes, mutations 
and mRNA expression profiles of 47 ovarian cancer cell lines with the TCGA data. 
Twelve of these cell lines were defined as ‘likely high-grade serous’ but some of the 
commonly used cell lines such as SKOV3, A2780 and IGROV-1 had little profile 
similarities to high grade serous cancer. IGROV-1 was hypermutated and it clustered 
more with endometrioid and clear cell ovarian tumours. Therefore, this experiment 
needs to be repeated with a cell line which is more representative of HGSC [200]. 
9.1.5 Does this study suggest any possible combination therapy to 
target with an anti-IL-6 antibody? 
 
The observed differences in the IL-6 and VEGF signalling on endothelial cells 
further prompted me to study the dependency of IL-6 on VEGF in the aortic ring 
assay by using a VEGFR inhibitor. The results further confirmed previous finding 
suggesting IL-6 could induce sprouting in the aortic ring assay in the presence of a 
VEGFR inhibitor. Further studies into understanding the effects of VEGFR 
inhibition on endothelial cells showed upregulation of pSTAT3 in the VEGFRi + IL-
6 group as compared to the IL-6 treatment alone. This finding was further supported 
by α-SMA staining of the aortic ring vessels which showed further reduced pericyte 
coverage in the VEGFRi + IL-6 treated vessels as compared to vessels treated with 
IL-6 or VEGF alone. This was an interesting finding which indicated the potential 
for combining an anti-IL-6 agent with a VEGF inhibitor. 
Earlier studies looking at biomarker of response and resistance to anti-angiogenic 
therapies have identified elevated plasma levels of IL-6 after sunitinib treatment to be 
associated with poor outcome in patients with advanced HCC and renal cell 
carcinoma [160, 201]. Bevacizumab treatment along with chemoradiotherapy also 
increased plasma levels of IL-6 in the rectal cancer patients [169]. Alongside this 
there have been several studies showing the involvement of IL-6 pathway i.e. 
pSTAT3 in bevacizumab treatment failure in glioblastoma patients [159]. In the 
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bevacizumab resistant glioblastoma tumours there was a 40% increase in pSTAT3 
expression compared to pretreatment samples from the same patients [97]. 
Moreover, none of these studies have specifically looked at the effects of VEGFR 
inhibition on IL-6 production by endothelial cells. Hence, findings from these studies 
along with my preliminary data indicate a potential for combining a VEGFR 
inhibitor with an anti-IL-6 antibody to target the tumour vasculature.  
Therefore, using the IGROV-1 cells I studied the effects of VEGFR inhibition +/- 
anti-IL-6 antibody on pSTAT3 levels in malignant cells. Surprisingly, VEGFR 
inhibition decreased the expression of pSTAT3 in the IL-6 producing cell line 
IGROV-1 and the combination therapy with VEGFRi and anti-IL-6 antibody further 
reduced pSTAT3 levels. This indicated that VEGFR inhibition has different effects 
on malignant and endothelial cells in the presence of IL-6.  
In summary the ex vivo, in vitro and in vivo studies have shown IL-6 to be a potent 
angiogenic agent in normal and tumour angiogenesis. However the type of 
angiogenesis stimulated by IL-6 is aberrant with very few pericytes associated vessels 
compared to the VEGF induced angiogenesis. Also, IL-6 seems to have differential 
mechanism of inducing angiogenesis in MLEC as compared to VEGF. The positive 
regulation of Jagged1 and Ang2 by IL-6 and DLL4 by VEGF could explain the 
differences in pericyte coverage observed in the IL-6 and VEGF treated vessels. 
Studies with VEGFR inhibitor on endothelial cells have also suggested the potential 
for combining anti-VEGF therapies with anti-IL-6 antibodies. However more 
detailed experiments should be executed to substantiate these findings further and 
this will be addressed in the future studies section. 
A summary of the proposed mechanism of action of IL-6, VEGF and VEGFR 
inhibitor on endothelial cells is shown in Figure 9.1. 
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Figure 9.1 Showing the proposed mechanism of action of IL-6, VEGF and 
VEGFR inhibitor on endothelial cells.  
A) VEGFA binding to VEGF receptor leads to upregulation of DLL4 resulting in angiogenesis and 
maturation of vessels. However, IL-6 forms a complex with IL-6 receptors to activate Jagged1 and 
Ang2 resulting in angiogenesis with weak or defective pericyte coverage. B) VEGF inhibition in the 
presence of IL-6 leads to further upregulation of pSTAT3 resulting in angiogenesis with even weaker 
pericyte coverage.                              Outcome 
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9.2 Future work 
 
There are two main areas of research that I now would like to pursue. First, relates to 
the angiogenic actions of IL-6 and second on combining IL-6 antagonist with other 
angiogenic inhibitors in treatment of ovarian cancer. 
9.2.1 Effects of IL-6 on angiogenesis 
 
This work will be carried out using the aortic ring assay and in vitro MLEC cells. 
Aortic ring assay  
 
    - VEGF in combination with IL-6  
 
VEGF treatment led to formation of vessels with good pericyte coverage and 
IL-6 treatment led to vessels with poor pericyte coverage (refer to chapter 5). 
Therefore, it would be interesting to study the effects of combining IL-6 and 
VEGF in the aortic ring assay to investigate if VEGF treatment can restore the 
pericyte coverage in the presence of IL-6. 
 
  -  Extract protein from aortas treated with VEGF or IL-6 
 
Investigations into the mechanism of action of IL-6 and VEGF induced 
angiogenesis were carried out in MLEC cells, in vivo xenografts and in the 
HGSC dataset (refer to chapter 4,6 and 8).  Although it would be technically 
challenging, analysis of the ligands Jagged1, DLL4 and Ang2 from protein 
extracted from the aortas would give further validation of the mechanism of 
action of IL-6 and VEGF.  
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   -  Knock down of Jagged1 in the aortic ring assay 
 
Studies into mechanism of action of IL-6 have so far suggested a potential role 
of Jagged1 mediated angiogenic response. Transient gene silencing with 
siRNA constructs can be delivered to the aortic ring tissue using 
oligofectamine transfection [176]. In order to quantify the gene knockdown 
efficiency, RNA or protein can be extracted from the aortic tissue and the 
endogenous level of Jagged1 RNA/protein levels could be measured in the 
different treatment groups.  Therefore knockdown of Jagged1 in the  aortic 
ring will provide a means of testing the dependency of IL-6 on Jagged1 in 
sprouting angiogenesis.  
 
In vitro studies 
 
  -  IL-6 effects on a pericyte cell line 
 
 
Vascular membrane matrices are important for endothelial tube stabilisation. 
Laminin, collagen IV and fibronectin are structural components that facilitate 
assembly of vascular basement membranes. In vitro and in vivo studies have 
shown that pericyte recruitment to endothelial tubes is essential to stimulate 
vascular basement membrane matrix assembly [202].  Endothelial or pericyte 
only culture studies have shown little or no deposition of these structural 
proteins indicating the importance of requirement of both the cell types for the 
proper assembly of the basement membrane [203]. Therefore, using an in vitro 
3D endothelial/pericyte co-culture systems I would like to study the effects of 
IL-6 or VEGF on vascular basement membrane assembly [204].  
  -  IL-6 effects on MLEC 
 
Following on from the previous point, pericyte recruitment to the developing 
tube and subsequent stabilisation of vascular basement membrane requires 
effective PDGF-BB and HB-EGF signalling [205]. Therefore, I would like to 
study the changes in receptor expression in MLEC after treatment with IL-6 
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or VEGF using the mouse phospho receptor tyrosine kinase array.  This is a 
screening tool designed to detect the relative phosphorylation of 39 different 
RTKs including the PDGFR, TIE, VEGF, EGFR and so on. 
 
9.2.2 Combination of IL-6 targeting agents with angiogenic inhibitors 
 
In view of my data on the effects of VEGFR inhibitor on endothelial cells, I would 
combine VEGF/VEGFR inhibitors with anti-IL-6 antibodies in models of ovarian 
cancer, especially HGSC. 
In vivo studies with cediranib and anti-IL-6  
 
- IGROV-1 xenografts or even patient derived xenografts with relevant genetic 
mutations or relevant cell lines that we now have characterised as HGSC 
 
Patient derived tumours tissues at low passages are biologically stable and 
reflect the patient tumour with regards to histopathology, gene expression, 
gene mutations and therapeutic response [206]. IGROV-1 human xenografts 
models or patient derived tumour tissue with relevant genetic mutations such 
as P53, PTEN and BRCA would be used for efficacy and toxicity studies with 
anti-IL-6 and VEGFR inhibitors.  These models would also be used to study 
the tumour vasculature in terms of vessel maturation and pericyte coverage in 
the different treatment groups i.e. anti-VEGF +/- anti-IL-6.  
 
        -  Syngeneic models  
 
Syngeneic models involve the use of tumours derived from the same genetic 
background as the host. The use of syngeneic model will be beneficial to 
study the effects of the treatment on the tumour microenvironment in 
immunocompetent mice. Therefore, along with studying the effects of anti-
IL-6 and VEGFR inhibition on the tumour vasculature, investigation could 
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also be carried out to investigate the effects of combination treatment on 
the leukocyte infiltrate.   
 
In these models it would be interesting to study different treatment schedules 
of the two agents. There is also a potential of translating to clinical trial 
because both cediranib (VEGFR inhibitor) and anti-IL-6 have been tested in 
HGSC patients.  
 
Jak inhibitors instead of anti-IL-6 
 
In vitro and in vivo Anti-IL-6 studies in HGSC cell lines have shown inhibition 
of pSTAT3 levels with a compensatory effect observed in pERK and pEGFR 
signalling. However, in vitro studies with the JAK inhibitors in HGSC cell 
lines resulted in potent inhibition of pSTAT3 along with inhibition of pERK 
and pEGFR signalling suggesting no compensatory mechanism with the JAK 
inhibitors as opposed to the anti-IL-6 antibody (data not shown). Therefore, if 
in vitro combination studies with anti-IL-6 antibody and VEGFR inhibitors in 
HGSC cell lines show increase in EGFR signalling, I would like to carry out 
in vitro and in vivo studies testing the efficacy of combining JAK and VEGF 
inhibitors. 
 
More in vitro experiments with HGSC cell lines and MLEC 
 
 
As shown in chapter 8, more mechanistic in vitro studies with anti-IL-6 
antibody and VEGFR inhibitors would be carried out to study the effects of 
combination therapy on downstream IL-6 and VEGF signalling i.e. pSTAT3, 
pVEGFR, pERK. These experiments would be carried out at different time 
points in more relevant HGSC cell lines. Alongside this, further MLEC 
studies would be carried out to understand the mechanism of increased 
pSTAT3 expression in the IL-6 and VEGFRi treated groups at various early 
time points.  
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Studies in other cancer types 
 
Ovarian clear cell carcinoma and renal cell carcinoma are also high IL-6 
producing tumours. CCCs have a strong IL-6/pSTAT3/HIF-1 signature, 
which is an independent prognostic factor [207]. Previous studies have 
indicated an anti-angiogenic effect with anti-IL-6 antibody in ovarian clear 
cell carcinoma [35]. The in vivo anti-IL-6 studies in clear cell carcinoma 
showed reduction in tumour vasculature with normalisation of blood vessels 
[35]. Also as previously mentioned, IL-6 was associated with anti-VEGF 
therapy resistance in renal cell carcinoma [201]. Therefore, it would be 
interesting to carry out in vitro and in vivo combination studies with anti-IL-6 
and anti-VEGF agents in these clear cell carcinomas where IL-6 have been 
shown to contribute to either angiogeneis or anti-angiogenic therpay 
resistance.  
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